HGVSc	SYMBOL	Consequence	gnomADe_non_cancer_AN_nfe	gnomADe_non_cancer_AC_nfe	gnomADg_AN_nfe	gnomADg_AC_nfe	clinvar_clnsig	clinvar_golden_stars	clinvar_rs	clinvar_trait	ClinVar	ClinVar_ALLELEID	ClinVar_CLNDN	ClinVar_CLNDNINCL	ClinVar_CLNDISDB	ClinVar_CLNDISDBINCL	ClinVar_CLNHGVS	ClinVar_CLNREVSTAT	ClinVar_CLNSIG	ClinVar_CLNSIGCONF	ClinVar_CLNSIGINCL	ClinVar_CLNVC	ClinVar_CLNVCSO	ClinVar_CLNVI	ClinVar_DBVARID	ClinVar_GENEINFO	ClinVar_MC	ClinVar_ORIGIN	ClinVar_RS	ClinVar_SSR	ClinVar_CLNSUBA	ClinVar_CLNSIGA	ClinVar_CLNDATEA	ClinVar_CLNDATESUBA	ClinVar_CLNREVSTATA	ClinVar_CLNORA	ClinVar_CLNSCVA	ClinVar_CLNDNA	ClinVar_CLNCOMA
NM_001128425.1:c.933+3A>C	MUTYH	splice_region_variant,intron_variant	102730	14	15420	2	-	-	-	-	135992	139704	Colon_cancer|Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|MUTYH-associated_polyposis|not_provided	-	Human_Phenotype_Ontology:HP:0003003,MedGen:C0007102|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:C3272841|MedGen:CN517202	-	NC_000001.10:g.45797835T>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	University_Medical_Centre_Ljubljana:CMGVARID00681	-	MUTYH:4595	SO:0001627|intron_variant	1	587780751	-	Invitae|Counsyl|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Mendelics|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Ambry_Genetics|Color|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance	2018-12-31|2016-03-18|2014-10-10|2016-03-28|2018-07-02|2018-10-10|2018-10-01|2016-06-20|2018-11-21|2015-07-09|2019-01-18|2016-02-08|2017-01-01	2019-03-28|2016-11-23|2017-04-19|2019-03-21|2018-08-20|2019-08-02|2020-02-26|2017-01-26|2019-01-29|2018-09-19|2020-03-06|2018-01-25|2017-12-08	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|unknown	SCV000166462|SCV000487342|SCV000592702|SCV000711785|SCV000837759|SCV000993568|SCV000184317|SCV000537683|SCV000211413|SCV000331108|SCV001134490|SCV000697716|SCV000747463	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|MUTYH-associated_polyposis|Colon_cancer	This_sequence_change_falls_in_intron_10_of_the_MUTYH_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_MUTYH_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs587780751,_0.01%)._This_variant_has_been_reported_in_the_literature_as_homozygous_or_in_trans_with_pathogenic_variants_in_multiple_individuals_affected_with_adenomatous_polyposis_and_it_is_considered_a_founder_mutation_for_MUTYH-associated_polyposis_in_North-Eastern_Italy_(PMID:_12853198,_16616356,_19732775,_22773231,_22865608)._This_variant_is_also_known_as_c.891+3A>C_in_the_literature._Clinvar_contains_an_entry_for_this_variant_(Variation_ID:_135992)._This_variant_falls_in_intron_10_of_the_MUTYH_mRNA_and_is_reported_to_cause_skipping_of_exon_10Â¬â€ (PMID:Â¬â€ 16616356,Â¬â€ 22865608)._The_absence_of_exon_10_in_the_MUTYH_mRNA_results_in_a_translational_frameshift_and_premature_stop_codon_(p.Gly264TrpfsX7),_which_ultimately_leads_to_nonsense_mediated_decay_and_severely_impaired_expression_of_the_MUTYH_mRNA_and_protein_(PMID:_16616356,_22865608,Â¬â€ 23108399)._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||The_c.933+3A>C_variant_in_MUTYH_has_been_previously_reported_in_24_individuals_(_23_were_compound_heterozygotes,_1_was_a_homozygote,_and_1_was_a_heterozygote)_wi_th_MUTYH-related_attenuated_familial_adenomatous_polyposis_(FAP)and_segregated_w_ith_disease_in_7_affected_family_members_(Sampson_2003,_Vogt_2009,_Pin_2013)._It_has_been_identified_in_7/66554_of_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_http://exac.broadinstitute.org:_dbSNP_rs587780751)._This_freq_uency_is_low_enough_to_be_consistent_with_the_carrier_frequency_of_MUTYH-related_attenuated_FAP_in_the_general_population._This_variant_is_located_in_the_5'_spl_ice_region._Computational_tools_do_suggest_an_impact_to_splicing_and_functional_studies_provide_evidence_that_this_variant_alters_splicing_(Pin_2013)._In_summar_y,_this_variant_meets_criteria_to_be_classified_as_pathogenic_for_FAP_in_an_aut_osomal_recessive_manner_based_on_the_reported_number_of_probands,_segregations,_and_functional_studies.|||Functionally-validated_splicing_mutation_:Detected_in_individual(s)_satisfying_established_diagnostic_criteria_for_classic_disease_in_trans_with_a_mutation_or_mutation_is_homozygous:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||This_variant_is_denoted_MUTYH_c.933+3A>C_or_IVS10+3A>C_and_consists_of_an_A>C_nucleotide_substitution_at_the_+3_position_of_intron_10_of_the_MUTYH_gene._This_variant,_also_published_as_891+3A>C_or_Gly250TrpfsX7,_has_been_reported_in_multiple_polyposis_and_colorectal_cancer_patients,_is_considered_a_founder_variant_in_Italian_populations,_and_has_been_demonstrated_to_cause_skipping_of_exon_10_(Sampson_2003,_Kanter-Smoler_2006,_Olschwang_2007,_Vogt_2009,_Pin_2012,_Ruggieri_2013,_Yurgelun_2015)._MUTYH_c.933+3A>C_was_observed_at_an_allele_frequency_of_0.01%_(17/126656)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._Based_on_the_current_evidence,_we_consider_this_variant_to_be_pathogenic.||The_best_available_variant_frequency_is_uninformative._Found_in_at_least_one_symptomatic_patient._Predicted_to_negatively_affect_a_known_splice_site._Nucleotide_conservation_is_uninformative._Occurs_in_multiple_cases_with_a_recessive_pathogenic_variant_in_the_same_gene._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.|Variant_summary:_MUTYH_c.933+3A>C_variant_affects_a_non-conserved_intronic_nucleotide._Mutation_Taster_predicts_a_damaging_outcome_for_this_variant,_and_5/5_Alamut_algorithms_predict_the_variant_to_alter_normal_splicing,_which_is_supported_by_patient_cDNA_showing_that_this_variant_results_in_a_fusion_of_exon_9_to_exon_11._This_variant_is_found_in_8/124162_control_chromosomes_at_a_frequency_of_0.0000644,_which_does_not_significantly_exceed_maximal_expected_frequency_of_a_pathogenic_allele_(0.0055902)._However,_the_variant_has_been_cited_in_numerous_CRC_patients_in_the_literature._In_addition,_several_diagnostic_clinical_laboratories_and_databases_classified_this_variant_as_pathogenic._Taken_together,_this_is_a_disease_variant_and_was_classified_as_pathogenic.|
NM_001128425.1:c.700G>A	MUTYH	missense_variant	102462	18	15414	4	-	-	-	-	135989	139701	Hereditary_cancer-predisposing_syndrome|MYH-associated_polyposis|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1837991,OMIM:608456,Orphanet:ORPHA247798|MedGen:CN169374|MedGen:CN517202	-	NC_000001.10:g.45798151C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(11)	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:1204684	-	MUTYH:4595	SO:0001619|non-coding_transcript_variant	1	200165598	-	Invitae|Counsyl|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano	Uncertain_significance|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2018-12-28|2015-11-18|2018-02-16|2019-02-08|2018-06-07|2017-03-18|2017-01-11|2019-05-04|2018-07-31|2016-12-05|2017-07-25|2017-03-18	2019-03-28|2016-11-23|2018-11-05|2020-02-26|2018-11-06|2017-08-01|2019-03-21|2019-08-05|2019-01-29|2018-01-25|2018-01-29|2018-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000166457|SCV000487314|SCV000788256|SCV000186820|SCV000685660|SCV000601657|SCV000712773|SCV001159672|SCV000211403|SCV000697707|SCV000806366|SCV000889534	MYH-associated_polyposis|MYH-associated_polyposis|MYH-associated_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|not_specified|not_provided|not_provided|not_provided|not_provided	This_sequence_change_replaces_valine_with_methionine_at_codon_234_of_the_MUTYH_protein_(p.Val234Met)._The_valine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_valine_and_methionine._This_variant_is_present_in_population_databases_(rs200165598,_ExAC_0.02%)._This_variant_has_been_reported_in_individuals_and_families_affected_with_colon_cancer_(PMID:_16774938,_14991577)._This_variant_is_also_known_as_c.658G>A_(p.Val220Met)_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_135989)._Experimental_studies_have_shown_that_this_missense_change_partially_impairs_MUTYH_protein_function_(PMID:_25820570,_26694661)._The_clinical_significance_of_this_finding_is_unknown._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.||The_MUTYH_variant_designated_as_NM_001128425.1:c.700G>A_(p.Val234Met)_is_classified_as_likely_pathogenic._In_one_observed_family,_this_variant_co-occurs_with_a_known_pathogenic_variant_(MUTYH_p.Tyr179Cys_or_p.Y179C)_in_MUTYH_in_five_siblings_who_each_have_a_documented_history_of_multiple_colon_polyps_and/or_colon_cancer._The_variant_was_shown_to_be_in_trans_configuration_with_the_MUTYH_p.Y179C_variant._This_genomic_position_is_highly_conserved._Experimental_studies_of_this_variant_have_shown_that_it_partially_impairs_MUTYH_protein_function_(Komine_2015,_PMID:_25820570)._This_variant_is_listed_in_population_databases_and_is_present_in_1/5500_individuals_of_European_descent_(exac.broadinstitute.org)._Bayesian_analysis_integrating_all_of_this_data_(Tavtigian_et_al,_2018)_gives_about_98%_probability_of_pathogenicity,_which_is_consistent_with_a_classification_of_likely_pathogenic._MUTYH_p.Val234Met_is_expected_to_alter_MUTYH_function_and_increase_the_risk_of_developing_colon_cancer,_multiple_colon_polyps,_and_other_features_of_MYH-associated_polyposis_when_it_co-occurs_with_a_pathogenic_mutation_in_MUTYH_(Morak_2010,_PMID_20618354:_Grover_2012,_PMID:_22851115)._This_analysis_was_performed_in_conjunction_with_the_family_studies_project_as_part_of_the_University_of_Washington_Find_My_Variant_Study.|Insufficient_or_conflicting_evidence|||The_p.Val234Met_variant_in_MUTYH_has_been_reported_in_2_individuals_with_colorec_tal_cancer_(Fleischmann_2004,_Peterlongo_2006)._In_vitro_functional_studies_are_contradictory_with_one_study_providing_evidence_that_the_p.Val234Met_variant_may_impact_protein_function_(Komine_2015),_while_another_study_showed_that_the_prot_ein_function_is_fully_retained_(Shinmura_2016)._However,_these_types_of_assays_m_ay_not_accurately_represent_biological_function._This_variant_has_been_identifie_d_in_15/65590_European_chromosomes_by_the_Exome_Aggregation_Consortium_(ExAC,_ht_tp://exac.broadinstitute.org:_dbSNP_rs200165598)._Computational_prediction_tools_and_conservation_analysis_do_not_provide_strong_support_for_or_against_an_impac_t_to_the_protein._In_summary,_the_clinical_significance_of_the_p.Val234Met_varia_nt_is_uncertain.|The_MUTYH_c.700G>A:_p.Val234Met_variant_(rs200165598),_also_known_as_Val220Met_for_traditional_nomenclature,_is_reported_in_the_literature_in_individuals_with_colorectal_cancer_but_a_second_MUTYH_variant_was_not_identified_(Fleischmann_2004,_Peterlongo_2006,_Yurgelun_2015)._Our_laboratory_has_identified_this_variant_previously_in_an_individual_with_a_personal_and_family_history_of_colon_cancer,_who_also_carried_a_pathogenic_MUTYH_frameshift_variant._One_functional_study_shows_that_the_p.Val234Met_variant_protein_has_partially_defective_function_(Komine_2015),_while_another_study_shows_the_variant_protein_retains_normal_repair_activity_(Shinmura_2016)._This_variant_is_reported_in_ClinVar_(Variation_ID:_135989)._It_is_found_in_the_general_European_(non-Finnish)_population_with_an_allele_frequency_of_0.02%_(23/128662_alleles)_in_the_Genome_Aggregation_Database._Due_to_limited_information,_the_significance_of_this_variant_is_uncertain_at_this_time._REFERENCES_Fleischmann_C_et_al._Comprehensive_analysis_of_the_contribution_of_germline_MYH_variation_to_early-onset_colorectal_cancer._Int_J_Cancer._2004_Apr_20:109(4):554-8._Komine_K_et_al._Functional_Complementation_Assay_for_47_MUTYH_Variants_in_a_MutY-Disrupted_Escherichia_coli_Strain._Hum_Mutat._2015_Jul:36(7):704-11._Peterlongo_P_et_al._Increased_frequency_of_disease-causing_MYH_mutations_in_colon_cancer_families._Carcinogenesis._2006_Nov:27(11):2243-9._Shinmura_K_et_al._Functional_Evaluation_of_Nine_Missense-Type_Variants_of_the_Human_DNA_Glycosylase_Enzyme_MUTYH_in_the_Japanese_Population._Hum_Mutat._2016_Apr:37(4):350-3._Yurgelun_MB_et_al._Identification_of_a_Variety_of_Mutations_in_Cancer_Predisposition_Genes_in_Patients_With_Suspected_Lynch_Syndrome._Gastroenterology._2015_Sep:149(3):604-13.e20.|This_variant_is_denoted_MUTYH_c.700G>A_at_the_cDNA_level,_p.Val234Met_(V234M)_at_the_protein_level,_and_results_in_the_change_of_a_Valine_to_a_Methionine_(GTG>ATG)._MUTYH_Val234Met,_previously_reported_as_c.658G>A,_Val220Met,_and_Val206Met_using_alternate_transcripts,_has_been_reported_in_individuals_diagnosed_with_colon_cancer_as_well_as_in_healthy_controls_(Fleischmann_2004,_Peterlongo_2006,_DeRycke_2017)._While_Komine_et_al._(2015)_showed_MUTYH_Val234Met_to_have_partially_defective_base_excision_repair_activity_in_an_E._coli-based_complementation_assay,_Shinmura_et_al._(2015)_reported_this_variant_to_have_almost_fully_retained_DNA_glycosylase_activity_in_vitro_and_mutation_suppression_ability_similar_to_wild-type_in_a_human_cell_line._MUTYH_Val234Met_was_observed_at_an_allele_frequency_of_0.02%_(24/126,336)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_MSH6_binding_domain_(Gu_2002,_Ruggieri_2013)._While_protein-based_in-silico_analysis_supports_that_this_variant_does_not_alter_protein_structure/function,_multiple_splicing_based_in-silico_models_predict_that_this_variant_may_create_a_cryptic_splice_donor_site_upstream_of_the_nearby_natural_splice_donor_site._However,_in_the_absence_of_RNA_or_functional_studies,_the_actual_effect_of_this_variant_on_splicing_is_unknown._Based_on_currently_available_evidence,_it_is_unclear_whether_MUTYH_Val234Met_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance._Of_note,_MUTYH-Associated_Polyposis_(MAP)_is_a_recessive_condition_associated_with_two_MUTYH_pathogenic_variants_on_opposite_chromosomes.|||
NM_000251.2:c.1045C>G	MSH2	missense_variant	102700	3	15428	1	-	-	-	-	90512	95987	Renal_cell_carcinoma,_papillary,_1|Hereditary_cancer-predisposing_syndrome|Turcot_syndrome|Muir-Torré_syndrome|Lynch_syndrome|Lynch_syndrome_I|not_provided	-	Human_Phenotype_Ontology:HP:0005584,MeSH:D002292,MedGen:C0007134,OMIM:605074,Orphanet:ORPHA217071,SNOMED_CT:41607009|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0265325,OMIM:276300,Orphanet:ORPHA252202,SNOMED_CT:61665008|MedGen:C1321489,OMIM:158320,Orphanet:ORPHA587,SNOMED_CT:403824007|MedGen:C1333990,Orphanet:ORPHA144|MedGen:C2936783,OMIM:120435|MedGen:CN517202	-	NC_000002.11:g.47643537C>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_benign(1),Pathogenic(1),Uncertain_significance(8)	-	single_nucleotide_variant	SO:0001483	International_Society_for_Gastrointestinal_Hereditary_Tumours_(InSiGHT):c.1045C>G	-	MSH2:4436	SO:0001583|missense_variant	3	267607939	-	Mendelics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Ambry_Genetics|Color|True_Health_Diagnostics|CSER__CC_NCGL,_University_of_Washington|GeneDx|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Fulgent_Genetics,Fulgent_Genetics|Mendelics	Uncertain_significance|Pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_benign|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2018-07-02|2018-05-01|2018-11-14|2018-06-20|2017-08-11|2014-06-01|2018-10-25|2019-03-01|2017-04-06|2018-09-05|2018-10-31|2019-05-28	2018-08-20|2018-12-28|2020-02-26|2018-11-06|2018-03-08|2014-08-28|2019-01-29|2019-03-14|2018-01-25|2020-03-06|2018-11-14|2019-10-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|somatic|germline|germline|germline|germline|germline|germline|germline|germline|unknown|unknown	SCV000837825|SCV000887410|SCV000172803|SCV000684897|SCV000788028|SCV000190350|SCV000211170|SCV000254377|SCV000696197|SCV001134327|SCV000895480|SCV001135721	Lynch_syndrome|Lynch_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Renal_cell_carcinoma,_papillary,_1|not_provided|not_provided|not_provided|not_provided|Lynch_syndrome_I/Turcot_syndrome/Muir-Torré_syndrome|Lynch_syndrome_I	|MSH2_NM_000251.2:c.1045C>G_has_a_99.6%_probability_of_pathogenicity_based_on_combining_prior_probability_from_public_data_with_a_likelihood_ratio_of_26.5_to_1,_generated_from_evidence_of_seeing_this_as_a_somatic_mutation_in_a_tumor_with_loss_of_heterozygosity_at_the_MSH2_locus._See_Shirts_et_al_2018,_PMID_29887214.|Conflicting_evidence||||This_variant_is_denoted_MSH2_c.1045C>G_at_the_cDNA_level,_p.Pro349Ala_(P349A)_at_the_protein_level,_and_results_in_the_change_of_a_Proline_to_an_Alanine_(CCT>GCT)._This_variant_has_been_reported_in_individuals_with_colorectal,_breast,_or_other_cancers,_as_well_as_in_an_Ashkenazi_Jewish_control_subject_(Rubio-Del-Campo_2008,_Carmi_2014,_Cragun_2014,_Hansen_2017,_Jalkh_2017,_Zidan_2017)._This_variant_did_not_result_in_6TG-resistant_colony_formation,_suggesting_it_does_not_affect_mismatch_repair_function_(Houlleberghs_2016)._MSH2_Pro349Ala_was_observed_at_an_allele_frequency_of_0.079%_(8/10,148)_in_individuals_of_Ashkenazi_Jewish_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_Lever_domain_(Lutzen_2008,_Kansikas_2011)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_it_is_unclear_whether_MSH2_Pro349Ala_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.||Variant_summary:_The_MSH2_c.1045C>G_(p.Pro349Ala)_variant_involves_the_alteration_of_a_conserved_nucleotide,_resulting_in_a_missense_substitution._The_variant_lies_within_the_DNA_mismatch_repair_protein_MutS,_core_(InterPro)_and_4/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant_(SNPs&GO_not_captured_due_to_low_reliability_index)._This_variant_was_found_in_the_large_control_database_ExAC_at_a_frequency_of_0.0000906_(11/121390_control_chromosomes),_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MSH2_variant_(0.0005683)._However,_it_is_relatively_common_in_the_Latino_subpopulation_at_a_frequency_of_0.000346_(4/11574_in_ExAC:_13/34410_in_gnomAD)._For_this_subpopulation,_the_frequency_is_about_1_times_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_MSH2_variant_(0.0005683),_suggesting_this_may_be_a_benign_polymorphism._The_variant_has_been_cited_in_publications_numerous_times_with_conflicting_classifications,_including_likely_pathogenic_(Cragun_Clin_Genet_2014:_LaDuca_GIM_2014),_VUS_(Hansen_Clin_Genet_2017),_and_non-pathogenic_(Houlleberghs_PNAS_2016)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_uncertain_significance._A_functional_study_was_performed_in_cultured_mouse_embryonic_stem_cells_that_suggested_the_amino_acid_residue_P349_may_be_a_critical_amino_acid_since_the_mutants_P349L_and_P349R_were_defective_in_MMR_function._However,_the_same_study_also_assayed_the_variant_of_interest,_P349A,_and_showed_this_variant_to_have_intact_MMR_activity,_suggesting_this_variant_specifically_has_little_to_no_impact_on_protein_function_(Houlleberghs_PNAS_2016)._Additionally,_the_variant_has_been_found_to_co-occur_with_other_pathogenic_variants._First,_in_the_INSiGHT_database,_a_male_patient_diagnosed_with_colorectal_cancer_carried_the_variant_along_with_the_MSH2_pathogenic_mutation_c.223_224delCT_(p.Leu75Alafs:_classified_as_pathogenic_by_INSiGHT_curators),_and_immunohistochemistry_showed_positive_for_MLH1,_MSH2,_and_PMS2,_with_microsatellite_instability_categorized_as_MSI-H._Second,_a_publication_that_performed_whole_exome_sequencing_on_Lebanese_breast_cancer_patients_(Jalkh_BMC_Med_Genom_2017)_showed_the_variant_in_a_patient_along_with_the_pathogenic_BRCA1_mutation_c.4327C>T_(p.R1443*),_which_is_pathogenic_in_ClinVar_based_on_16_submissions,_suggesting_it_is_unlikely_that_the_variant_contributes_to_the_phenotype_in_this_patient._Taking_all_information_together,_this_variant_is_classified_as_VUS_-_possibly_benign.|||
NM_000038.5:c.423-3T>A	APC	splice_region_variant,intron_variant	93956	34	14684	1	-	-	-	-	142189	151903	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|not_specified	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2713442,OMIM:175100|MedGen:CN169374	-	NC_000005.9:g.112111323T>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(4)	-	single_nucleotide_variant	SO:0001483	Mayo_Clinic:95	-	APC:324	SO:0001627|intron_variant	1	587782293	-	Ambry_Genetics|Color|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Invitae|Mendelics	Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2019-05-21|2018-10-26|0000-00-00|2016-02-10|2018-12-23|2019-05-28	2020-02-26|2018-11-06|2015-11-19|2017-04-19|2019-03-28|2019-10-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|unknown	SCV000186122|SCV000905871|SCV000256993|SCV000591027|SCV000814096|SCV001136873	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Rarity_in_general_population_databases_(dbsnp,_esp,_1000_genomes)||||This_sequence_change_falls_in_intron_4_of_the_APC_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_APC_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_observed_in_an_individual_with_typical_or_attenuated_FAP_and_individuals_undergoing_APC_testing_(PMID:_20223039,_23159591)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142189)._Nucleotide_substitutions_within_the_consensus_splice_site_are_a_relatively_common_cause_of_aberrant_splicing_(PMID:_17576681,_9536098)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|
NM_000038.5:c.835-4T>G	APC	splice_region_variant,intron_variant	102344	5	15428	1	-	-	-	-	421952	406490	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2713442,OMIM:175100|MedGen:CN240755|MedGen:CN517202	-	NC_000005.9:g.112151188T>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(4)	-	single_nucleotide_variant	SO:0001483	_Inc:APC-A3	-	APC:324	SO:0001627|intron_variant	1	756807560	-	_Inc|Color|Ambry_Genetics	Uncertain_significance|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Uncertain_significance	2016-08-12|2018-03-28|2016-11-01|2018-05-07|2018-03-16	2019-01-29|2018-08-29|2017-12-20|2018-11-06|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline	SCV000571299|SCV000647769|SCV000781067|SCV000912030|SCV001178701	not_provided|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	This_variant_is_denoted_APC_c.835-4T>G_or_IVS8-4T>G_and_consists_of_a_T>G_nucleotide_substitution_at_the_-4_position_of_intron_8_of_the_APC_gene._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature_as_pathogenic_or_benign._In_silico_models_are_inconclusive_with_respect_to_splicing,_and_in_the_absence_of_RNA_or_functional_studies,_the_actual_effect_of_this_variant_is_unknown._APC_c.835-4T>G_was_not_observed_in_approximately_6,500_individuals_of_European_and_African_American_ancestry_in_the_NHLBI_Exome_Sequencing_Project,_suggesting_it_is_not_a_common_benign_variant_in_these_populations._The_thymine_(T)_nucleotide_that_is_altered_is_not_conserved_across_species._Based_on_currently_available_information,_it_is_unclear_whether_APC_c.835-4T>G_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|This_sequence_change_falls_in_intron_8_of_the_APC_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_APC_protein._This_variant_is_present_in_population_databases_(rs756807560,_ExAC_0.006%)._This_variant_has_not_been_reported_in_the_literature_in_individuals_with_APC-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_421952)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_disrupt_the_consensus_splice_site,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||Insufficient_evidence
NM_000038.5:c.1240C>T	APC	missense_variant	102076	115	15426	7	5&2	0&1	rs137854567	Gardner syndrome&Hereditary cancer-predisposing syndrome	797	15836	Gardner_syndrome|Hereditary_cancer-predisposing_syndrome|Pilocytic_astrocytoma|Familial_adenomatous_polyposis_1|not_specified|APC-Associated_Polyposis_Disorders|not_provided	-	MedGen:C0017097,Orphanet:ORPHA79665,SNOMED_CT:60876000|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0334583,Orphanet:ORPHA251612|MedGen:C2713442,OMIM:175100|MedGen:CN169374|MedGen:CN239210|MedGen:CN517202	-	NC_000005.9:g.112154969C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Benign(3),Likely_benign(7),Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	Illumina:779984|OMIM_Allelic_Variant:611731.0005|UniProtKB_(protein):P25054#VAR_005033|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2788978	-	APC:324	SO:0001583|missense_variant	1	137854567	-	OMIM|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Ambry_Genetics|Color|True_Health_Diagnostics|ITMI|GeneDx|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|Pathway_Genomics|CSER__CC_NCGL,_University_of_Washington|Counsyl|Illumina_Clinical_Services_Laboratory,Illumina|Clinical_Genomics_Lab,St._Jude_Children's_Research_Hospital	Pathogenic|variant_of_unknown_significance|Benign|Benign|Likely_benign|Likely_benign|Likely_benign|Benign|Likely_benign|Likely_benign|not_provided|Likely_benign|Uncertain_significance|Likely_benign|Uncertain_significance|Uncertain_significance|Likely_benign|Likely_benign|Uncertain_significance	1991-08-09|2012-07-13|2019-03-05|2017-06-05|2017-09-01|2019-02-12|2018-04-01|2015-11-09|2016-10-04|2018-10-04|2013-09-19|2018-01-10|2017-01-25|0000-00-00|2014-07-24|2014-06-01|2018-05-15|2016-06-14|2016-08-05	2016-10-20|0000-00-00|2019-03-14|2018-01-25|2018-01-29|2020-03-06|2019-07-12|2020-02-26|2017-10-26|2018-11-27|2014-05-29|2018-03-26|2017-04-03|2017-10-31|2014-08-08|2014-08-28|2018-06-20|2016-10-18|2018-12-04	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|germline|germline	SCV000020983|SCV000043109|SCV000166014|SCV000693992|SCV000805365|SCV000887503|SCV000892420|SCV000172854|SCV000681448|SCV000886658|SCV000084188|SCV000148976|SCV000538298|SCV000691712|SCV000189870|SCV000190063|SCV000786455|SCV000451986|SCV000890940	Gardner_syndrome|not_provided|not_provided|not_provided|not_provided|not_provided|not_provided|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|not_specified|not_specified|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|APC-Associated_Polyposis_Disorders|Pilocytic_astrocytoma	|Converted_during_submission_to_Uncertain_significance.||Variant_summary:_The_APC_c.1240C>T_(p.Arg414Cys)_variant_causes_a_missense_change_involving_the_alteration_of_a_conserved_nucleotide._5/5_in_silico_tools_predict_a_damaging_outcome_for_this_variant._However,_a_functional_study_found_that_this_variant_maintained_inhibitory_activity_on_the_transcription_mediated_by_the_beta-catenin/TCF4_complex,_as_did_wild-type_APC._The_variant_of_interest_has_been_found_in_a_large,_broad_control_population,_ExAC_in_105/120892_control_chromosomes_at_a_frequency_of_0.0008685,_which_is_approximately_12_times_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_APC_variant_(0.0000714),_suggesting_this_variant_is_likely_a_benign_polymorphism._This_variant_was_found_in_multiple_studies_in_FAP_patients_(van_der_Klift_PMS2_Hum_Mutat_2016,_Azzopardi_CancerRsrch_2008)_but_one_functional_study_and_the_high_frequency_in_population_suggests_a_benign_effect._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_recently_classified_this_variant_as_likely_benign/benign._Taken_together,_this_variant_is_classified_as_benign.||||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Subpopulation_frequency_in_support_of_benign_classification:Co-occurence_with_a_mutation_in_another_gene_that_clearly_explains_a_proband's_phenotype:No_disease_association_in_appropriately_sized_case-control_study(ies)||||This_variant_is_considered_likely_benign_or_benign_based_on_one_or_more_of_the_following_criteria:_it_is_a_conservative_change,_it_occurs_at_a_poorly_conserved_position_in_the_protein,_it_is_predicted_to_be_benign_by_multiple_in_silico_algorithms,_and/or_has_population_frequency_not_consistent_with_disease.|Variant_identified_in_a_genome_or_exome_case(s)_and_assessed_due_to_predicted_null_impact_of_the_variant_or_pathogenic_assertions_in_the_literature_or_databases._Disclaimer:_This_variant_has_not_undergone_full_assessment._The_following_are_preliminary_notes:_Frequency_too_high_for_disease._Max_MAF_in_ExAC:_0.19%_(13_Finnish_alleles_and_90_European_alleles)_and_gnomAD:_0.18%_(47_Finnish_alleles_and_129_European_alleles)._Penetrance_of_APC_is_close_to_100%._It_has_been_reported_in_affected_and_unaffected_individuals._It_is_classified_in_ClinVar_as_Benign_by_Invitae_and_Ambry,_and_as_VUS_by_Biesecker,_CSER,_Pathway_genomics,_GeneDx.||||||
NM_000038.5:c.3949G>C	APC	missense_variant	102496	650	15432	77	2	0	rs1801166	not provided	829	15868	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|not_specified|APC-Associated_Polyposis_Disorders|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2713442,OMIM:175100|MedGen:CN169374|MedGen:CN239210|MedGen:CN517202	-	NC_000005.9:g.112175240G>C	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Benign(8),Likely_benign(5),Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	Illumina_Clinical_Services_Laboratory,Illumina:65344|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2686298|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:3381|UniProtKB_(protein):P25054#VAR_009617|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic:86|OMIM_Allelic_Variant:611731.0036	-	APC:324	SO:0001583|missense_variant	1	1801166	-	OMIM|GeneReviews|Pathway_Genomics|Counsyl|Mendelics|Biochemical_Molecular_Genetic_Laboratory,King_Abdulaziz_Medical_City|Biesecker_Lab/Clinical_Genomics_Section,National_Institutes_of_Health|Invitae|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|ITMI|GeneDx|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Illumina_Clinical_Services_Laboratory,Illumina|Color|True_Health_Diagnostics|Ambry_Genetics	Pathogenic|pathologic|Likely_benign|Likely_benign|Uncertain_significance|Benign|no_known_pathogenicity|Benign|Likely_benign|Benign|Likely_benign|not_provided|Benign|Benign|Uncertain_significance|Benign|Benign|Benign|Likely_benign|Benign|Likely_benign|Likely_benign	2000-09-22|2011-10-27|2014-07-24|2017-05-18|2018-07-02|2020-02-05|2012-07-13|2019-03-05|2017-05-01|2018-03-23|2017-05-08|2013-09-19|2013-10-10|2014-12-03|0000-00-00|0000-00-00|2016-02-05|2018-07-06|2016-06-14|2016-03-21|2017-08-11|2019-12-26	2016-10-20|2013-01-08|2014-08-08|2018-06-20|2018-08-20|2020-02-12|0000-00-00|2019-03-14|2019-07-12|2018-08-31|2019-03-21|2014-05-29|2018-03-26|2018-09-19|2017-10-31|2016-04-28|2017-04-19|2019-08-05|2016-10-18|2017-10-26|2017-11-15|2020-02-26	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter	germline|not_provided|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline|germline	SCV000021022|SCV000040394|SCV000189869|SCV000785169|SCV000838111|SCV001190845|SCV000043126|SCV000153870|SCV000609169|SCV000888740|SCV000058713|SCV000084172|SCV000167008|SCV000226386|SCV000256984|SCV000301593|SCV000591162|SCV000602523|SCV000452009|SCV000681643|SCV000693481|SCV001183123	Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|not_provided|not_provided|not_provided|not_provided|not_specified|not_specified|not_specified|not_specified|not_specified|not_specified|not_specified|not_specified|APC-Associated_Polyposis_Disorders|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome	|Converted_during_submission_to_Pathogenic.|||||Converted_during_submission_to_Benign.||||Disclaimer:_This_variant_has_not_undergone_full_assessment._The_following_are_pr_eliminary_notes:_This_variant_is_classified_in_HGMD_as_DP_and_is_present_in_12_p_apers,_with_comments_suggesting_non-pathogenicity._It_is_present_at_0.62%_in_gno_mAD_(785/126536_European_chrs,_including_7_homozygotes)._It_is_classified_in_Cli_nVar_with_1_star_as_Benign/Likely_benign_by_Invitae,_GeneDx,_Emory,_Prevention_G_enetics,_Biesecker_lab,_and_Pathway_Genomics._2_mammals_have_a_Gln_at_this_posit_ion.||This_variant_is_considered_likely_benign_or_benign_based_on_one_or_more_of_the_following_criteria:_it_is_a_conservative_change,_it_occurs_at_a_poorly_conserved_position_in_the_protein,_it_is_predicted_to_be_benign_by_multiple_in_silico_algorithms,_and/or_has_population_frequency_not_consistent_with_disease.|||||||||
NM_000038.5:c.6857C>T	APC	missense_variant	102340	25	15428	2	3&3	1&1	rs200587641	Hereditary cancer-predisposing syndrome&Familial adenomatous polyposis 1	127315	132772	Hereditary_cancer-predisposing_syndrome|Familial_adenomatous_polyposis_1|not_specified|Familial_adenomatous_polyposis|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2713442,OMIM:175100|MedGen:CN169374|MedGen:CN240755|MedGen:CN517202	-	NC_000005.9:g.112178148C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Benign(1),Likely_benign(4),Pathogenic(1),Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	-	-	APC:324	SO:0001583|missense_variant	1	200587641	-	Sinai_Health_System|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America	Likely_benign|Uncertain_significance|Likely_benign|not_provided|Likely_benign|Uncertain_significance|Uncertain_significance|Pathogenic|Benign|Likely_benign	2018-09-20|2018-08-01|2016-03-21|2013-09-19|2017-12-15|2018-03-27|2018-07-02|2015-11-20|2019-02-27|2017-01-19	2020-02-26|2018-08-08|2018-11-06|2014-05-29|2018-03-26|2018-06-20|2018-08-20|2017-10-30|2019-03-14|2018-01-25	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline	SCV000183908|SCV000821823|SCV000910682|SCV000084159|SCV000149025|SCV000786262|SCV000838144|SCV000591203|SCV000166053|SCV000694101	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis_1|Familial_adenomatous_polyposis|not_provided|not_provided	Other_data_supporting_benign_classification:In_silico_models_in_agreement_(benign):Co-occurence_with_mutation_in_same_gene_(phase_unknown)||||This_variant_is_considered_likely_benign_or_benign_based_on_one_or_more_of_the_following_criteria:_it_is_a_conservative_change,_it_occurs_at_a_poorly_conserved_position_in_the_protein,_it_is_predicted_to_be_benign_by_multiple_in_silico_algorithms,_and/or_has_population_frequency_not_consistent_with_disease.|||||Variant_summary:_The_APC_c.6857C>T_(p.Ala2286Val)_variant_involves_the_alteration_of_a_non-conserved_nucleotide._2/4_in_silico_tools_predict_a_benign_outcome_for_this_variant_(SNPs&GO_not_captured_due_to_low_reliability_index)._This_variant_was_found_in_31/121008_control_chromosomes_(1_homozygote)_at_a_frequency_of_0.0002562,_which_is_approximately_4_times_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_APC_variant_(0.0000714),_suggesting_this_variant_is_likely_a_benign_polymorphism._This_variant_has_been_reported_in_one_individual_who_also_carries_a_potenially_pathogenic_APC_variant_(c.896_897delCT/p.Ser299CysfsX27,_UMD_database)._In_addition,_at_least_one_clinical_diagnostics_laboratory_classified_this_variant_as_likely_benign._Taken_together,_this_variant_is_classified_as_likely_benign.
NM_002485.4:c.643C>T	NBN	missense_variant	102416	443	15414	43	3	1	rs34767364	Hereditary cancer-predisposing syndrome	6948	21987	_normal_intelligence_and_immunodeficiency|not_specified|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:CN169374|MedGen:CN517202	-	NC_000008.10:g.90983460G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Benign(2),Likely_benign(4),Uncertain_significance(7)	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):O60934#VAR_025799|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:102952|OMIM_Allelic_Variant:602667.0009	-	NBN:4683	SO:0001583|missense_variant	1	34767364	-	OMIM|GeneReviews|Counsyl|Mendelics|Ambry_Genetics|Color|True_Health_Diagnostics|GeneKor_MSA|ITMI|Genetic_Services_Laboratory,_University_of_Chicago|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Invitae|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics	Pathogenic|Pathogenic|Uncertain_significance|Likely_benign|Likely_benign|Benign|Likely_benign|Uncertain_significance|not_provided|Uncertain_significance|Likely_benign|Benign|Uncertain_significance|Uncertain_significance|Likely_benign|Uncertain_significance|Uncertain_significance	2006-03-01|2017-02-02|2017-03-24|2018-07-02|2019-04-28|2014-12-12|2017-09-05|2018-08-01|2013-09-19|2016-05-05|2018-07-24|2019-03-04|2018-06-07|2019-02-01|2019-01-15|2017-02-02|2016-08-23	2016-10-11|2017-02-02|2018-07-10|2018-08-20|2020-02-26|2017-10-26|2018-03-08|2018-08-08|2014-05-29|2017-07-05|2019-08-05|2019-03-14|2018-09-19|2019-07-12|2020-03-06|2018-01-25|2018-01-29	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000027562|SCV000494626|SCV000800508|SCV000838311|SCV000184001|SCV000685805|SCV000788081|SCV000822089|SCV000085819|SCV000595910|SCV000604434|SCV000166524|SCV000231654|SCV000575564|SCV000601698|SCV000697976|SCV000806447	Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Microcephaly,_normal_intelligence_and_immunodeficiency|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|not_specified|not_provided|not_provided|not_provided|not_provided|not_provided|not_provided	||||Intact_protein_function_observed_in_appropriate_functional_assay(s):Subpopulation_frequency_in_support_of_benign_classification:Seen_in_trans_with_a_mutation_or_in_homozygous_state_in_individual_without_severe_disease_for_that_gene:General_population_or_subpopulation_frequency_is_too_high_to_be_a_pathogenic_mutation_based_on_disease/syndrome_prevalence_and_penetrance|||||||||||Variant_summary:_The_NBN_c.643C>T_(p.Arg215Trp)_variant_involves_the_alteration_of_a_non-conserved_nucleotide._4/4_in_silico_tools_predict_a_damaging_outcome_for_this_variant_(SNPs&GO_not_captured_due_to_low_reliability_index)._This_variant_was_found_in_392/138390_control_chromosomes_(including_3_homozygotes)_at_a_frequency_of_0.0028326,_which_greater_(1.13_time)_than_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_NBN_variant_(0.0025)_based_on_the_disease_prevalence_of_NBS_(1_in_100000),_suggesting_this_variant_is_likely_a_benign_polymorphism._However,_the_frequency_in_general_population_is_in_sub-polymorphic_range_and_these_data_alone_cannot_rule_out_the_possibility_that_it_can_still_have_a_role_as_a_risk_variant_in_disease._Pathogenic_variants_in_this_gene_are_monogenically_linked_with_NBS_(Nijmegen_Breakage_Syndrome)_-_an_autosomal_recessive_disorder_as_well_as_associated_with_increased_risks_for_various_cancers._The_variant_has_been_reported_in_patients_with_various_cancers_such_as_breast_cancer,_leukemia,_prostate_cancer,_ovarian_cancer,_melanoma,_colorectal_cancer,_lung_cancer_etc._However,_it_has_not_been_reported_to_have_a_considerably_significant_association_with_other_forms_of_cancer_(Taylor_2003,_Hebbring_2006,_Bogdanovaas_2008,_Dzikiewicz-Krawczyk_2012,_and_Ramus_2014)._This_is_consistent_with_studies_reporting_95%_CI_around_the_OR_to_include_1.0,_thereby_providing_little_to_no_confidence_on_the_strength_of_the_assertions._Specifically,_this_variant_was_not_significantly_associated_with_increased_risk_for_breast_cancer_(Bogdanova_IJC_2008)_(adjusted_OR_
NM_002485.4:c.511A>G	NBN	missense_variant	102612	187	15422	108	5&2	0&1	rs61754966	Aplastic anemia&Microcephaly, normal intelligence and immunodeficiency	6946	21985	Aplastic_anemia|Acute_lymphoid_leukemia|Hereditary_cancer-predisposing_syndrome|Microcephaly,_normal_intelligence_and_immunodeficiency|Leukemia,_acute_lymphoblastic,_susceptibility_to|not_specified|not_provided	-	Human_Phenotype_Ontology:HP:0001915,MedGen:C0002874,OMIM:609135,Orphanet:ORPHA182040,SNOMED_CT:306058006|MedGen:C0023449,OMIM:613065,Orphanet:ORPHA513,SNOMED_CT:91857003|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C0398791,OMIM:251260,Orphanet:ORPHA647,SNOMED_CT:234638009|MedGen:C1840513|MedGen:CN169374|MedGen:CN517202	-	NC_000008.10:g.90990521T>C	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Benign(3),Likely_benign(1),Uncertain_significance(11)	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:162822|OMIM_Allelic_Variant:602667.0007|UniProtKB_(protein):O60934#VAR_025796	-	NBN:4683	SO:0001583|missense_variant	1	61754966	-	OMIM|OMIM|Ambry_Genetics|GeneID_Lab_-_Advanced_Molecular_Diagnostics|GeneKor_MSA|Color|ITMI|GeneDx|Genetic_Services_Laboratory,_University_of_Chicago|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|Mendelics|Soonchunhyang_University_Bucheon_Hospital,Soonchunhyang_University_Medical_Center|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Invitae|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|PreventionGenetics,PreventionGenetics|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Pathogenic|risk_factor|Likely_benign|Uncertain_significance|Uncertain_significance|Benign|not_provided|Uncertain_significance|Uncertain_significance|Uncertain_significance|Benign|Uncertain_significance|Uncertain_significance|Uncertain_significance|Benign|Uncertain_significance|Uncertain_significance|Uncertain_significance	2004-10-01|2004-10-01|2019-03-24|2017-09-07|2018-08-01|2015-11-09|2013-09-19|2017-06-16|2014-12-12|2017-02-18|2019-04-10|2018-07-02|2016-03-18|2015-03-16|2019-03-06|2018-07-01|2017-01-30|2017-06-07	2016-10-11|2016-10-11|2020-02-26|2017-09-11|2018-08-08|2018-11-06|2014-05-29|2017-11-28|2015-09-15|2017-08-01|2019-09-24|2018-08-20|2016-04-14|2018-09-19|2019-03-14|2019-07-12|2018-01-29|2018-10-10	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000027559|SCV000027560|SCV000186698|SCV000680449|SCV000822086|SCV000910544|SCV000085816|SCV000149706|SCV000248139|SCV000601696|SCV000697972|SCV000838314|SCV000267415|SCV000231035|SCV000252775|SCV000780919|SCV000806444|SCV000885817	Aplastic_anemia|Leukemia,_acute_lymphoblastic,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|not_specified|not_specified|not_specified|Microcephaly,_normal_intelligence_and_immunodeficiency|Acute_lymphoid_leukemia|not_provided|not_provided|not_provided|not_provided|not_provided	||Intact_protein_function_observed_in_appropriate_functional_assay(s):Subpopulation_frequency_in_support_of_benign_classification:Structural_Evidence:Seen_in_trans_with_a_mutation_or_in_homozygous_state_in_individual_without_severe_disease_for_that_gene|||||This_variant_is_denoted_NBN_c.511A>G_at_the_cDNA_level,_p.Ile171Val_(I171V)_at_the_protein_level,_and_results_in_the_change_of_an_Isoleucine_to_a_Valine_(ATT>GTT)._This_variant,_which_is_common_in_certain_Slavic_and_Asian_populations,_has_been_reported_as_a_possible_risk_factor_for_overall_cancer_risk_as_well_as_specific_cancers,_including_medulloblastoma,_lymphoma,_leukemia,_lung,_and_others_(Ziolkowska_2007,_Grajkowska_2009,_Ciara_2010,_Gao_2013,_Mosor_2013,_Kaluzna_2015,_Sykorova_2015)._Gao_et_al._(2013)_proposed_that_NBN_Ile171Val_could_be_a_low_penetrance_risk_factor_for_certain_types_of_cancer._Some_studies_observed_an_association_with_breast_cancer_(Roznowski_2008,_Yamamoto_2014,_Domagala_2015),_but_others_did_not_come_to_the_same_conclusion_(Kanka_2007,_Bogdanova_2008,_Zhang_2012,_Gao_2013,_Kim_2015)._While_NBN_pathogenic_variants_typically_cause_the_recessive_disease_Nijmegen_breakage_syndrome_(NBS),_a_case_report_describes_an_11_year_old_Japanese_girl_who_was_found_to_be_homozygous_for_this_variant_and_did_not_have_NBS,_though_she_did_have_aplastic_anemia_(Shimada_2004)._Results_from_functional_studies_have_been_inconsistent:_one_in_vitro_study_demonstrated_similar_behavior_to_wild_type_with_respect_to_damage_after_irradiation_(Dzikiewicz-Krawczyk_2012),_while_another_demonstrated_impaired_homologous_recombination,_aberrant_localization,_and_chromosomal_instability_(Yamamoto_2014)._NBN_Ile171Val_was_observed_with_allele_frequencies_of_0.6%_(5/826)_in_the_Japanese_population_(Shimada_2004)_and_0.2%_(14/8600)_in_European_Americans_in_the_NHLBI_Exome_Sequencing_Project._Since_Isoleucine_and_Valine_share_similar_properties,_this_is_considered_a_conservative_amino_acid_substitution._NBN_Ile171Val_occurs_at_a_position_that_is_conserved_across_species_and_is_located_in_the_BRCT_domain_as_well_as_the_region_mediating_interaction_with_SP100_(UniProt)._In_silico_analyses_are_inconsistent_regarding_the_effect_this_variant_may_have_on_protein_structure_and_function._In_summary,_while_the_data_are_inconsistent_with_respect_to_breast_cancer_risk,_this_variant_may_be_a_risk_factor_for_other_types_of_cancer._Furthermore,_the_variant_in_a_recessive_form_might_cause_diseases_other_than_typical_Nijmegen_breakage_syndrome._At_this_point,_it_is_unclear_whether_NBN_Ile171Val_is_a_benign_variant_or_a_low_penetrance_pathogenic_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|||Variant_summary:_NBN_c.511A>G_(p.Ile171Val)_results_in_a_conservative_amino_acid_change_located_in_the_BRCT_domain_of_the_encoded_protein_sequence._Three_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_0.0016_in_287466_control_chromosomes,_predominantly_at_a_frequency_of_0.0026_within_the_Non-Finnish_European_subpopulation_in_the_gnomAD_database._The_observed_variant_frequency_within_Non-Finnish_European_control_individuals_in_the_gnomAD_database_is_approximately_21_fold_of_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_NBN_causing_Hereditary_Breast_and_Ovarian_Cancer_phenotype_(0.00013),_strongly_suggesting_that_the_variant_is_a_benign_polymorphism_found_primarily_in_populations_of_Non-Finnish_European_origin._c.511A>G_has_been_reported_in_the_literature_in_individuals_affected_with_Breast_and_Ovarian_Cancer,_various_forms_of_leukemia_and_solid_tumors_(example_Taylor_2003,_Bogdanova_2008,_Grajkowska_2009,_Haiman_2013,_Kaluzna_2015,_Kim_2015,_Ramus_2015)._Several_of_these_predate_the_emergence_of_large_control_datasets_such_as_ExAC_and_gnomAD._Predominantly,_these_report(s)_do_not_provide_unequivocal_conclusions_about_the_association_of_the_variant_with_Hereditary_Breast_and_Ovarian_Cancer._Furthermore,_reports_of_association_with_other_forms_of_leukemia_and_solid_tumors_have_not_been_firmly_established._Co-occurrences_with_other_pathogenic_variant(s)_in_multiple_genes_have_been_reported_in_the_literature_as_well_as_in_our_own_testing_experience._Specifically,_BRCA1_c.3700_3704delGTAAA,_p.Val1234Glnfs_(Domagala_2015):_CHEK2_c.444+1G>A_(Domagala_2015:_BRCA2_c.6952C>T,_p.Arg2318X_(Internal_testing):_BRCA1,_not_specified:_and_PALB2,_not_specified_(Koczkowska_2018)._These_co-occurrences_provide_additional_supporting_evidence_for_a_benign_role._Multiple_publications_provide_conflicting_experimental_evidence_evaluating_an_impact_on_protein_function._Most_report_no_difference_in_measures_of_radiation_induced_DNA_damage_(Dzikiewicz-Krawczyk_2012),_cell_cycle_mediated_DNA_synthesis_and_chromosomal_instability_(Dzikiewicz-Krawczyk_2012,_Nowak_2017)._The_most_pronounced_variant_effect_results_in_reduced_double_stranded_repair_(DSB)_activity_through_loss_of_association_with_MDC1_(Yamamoto_2014)._Thirteen_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._Multiple_laboratories_reported_the_variant_with_conflicting_assessments_ranging_from_benign/likely_benign_(n
NM_000136.2:c.843+5G>A	FANCC	splice_region_variant,intron_variant	102730	3	15426	2	-	-	-	-	216291	212683	_complementation_group_C|not_provided	-	MedGen:C0015625,Orphanet:ORPHA84,SNOMED_CT:30575002|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C3468041,OMIM:227645|MedGen:CN517202	-	NC_000009.11:g.97897623C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(4)	-	single_nucleotide_variant	SO:0001483	-	-	FANCC:2176|AOPEP:84909	SO:0001627|intron_variant	1	369082921	-	Invitae|GeneDx|Counsyl|Mendelics|Ambry_Genetics	Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2018-11-06|2018-10-08|2017-03-16|2018-07-02|2019-12-13	2019-03-28|2019-01-29|2018-07-10|2018-08-20|2020-02-26	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|unknown|germline	SCV000254265|SCV000566528|SCV000790355|SCV000838349|SCV001178903	Fanconi_anemia|not_provided|Fanconi_anemia,_complementation_group_C|Fanconi_anemia,_complementation_group_C|Hereditary_cancer-predisposing_syndrome	This_sequence_change_falls_in_intron_8_of_the_FANCC_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_FANCC_protein,_but_it_affects_a_nucleotide_within_the_consensus_splice_site_of_the_intron._This_variant_is_present_in_population_databases_(rs369082921,_ExAC_0.01%)_but_has_not_been_reported_in_the_literature_in_individuals_with_a_FANCC-related_disease._ClinVar_contains_an_entry_for_this_variant_(Variant_ID:_216291)._Nucleotide_substitutions_at_the_+5_position_of_the_intron_are_relatively_common_causes_of_aberrant_splicing_(PMID:_17576681)._Algorithms_developed_to_predict_the_effect_of_nucleotide_changes_on_mRNA_splicing_suggest_that_this_variant_may_alter_mRNA_splicing,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_this_is_a_rare_intronic_change_with_uncertain_impact_on_splicing._It_has_been_classified_as_a_Variant_of_Uncertain_Significance.|This_variant_is_denoted_FANCC_c.843+5G>A_or_IVS8+5G>A_and_consists_of_a_G>A_nucleotide_substitution_at_the_+5_position_of_intron_8_of_the_FANCC_gene._In_silico_analyses,_which_include_splice_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect:_however,_in_the_absence_of_RNA_or_functional_studies,_the_actual_effect_of_this_variant_is_unknown._This_variant_has_not,_to_our_knowledge,_been_published_in_the_literature_as_a_pathogenic_or_benign_germline_variant._FANCC_c.843+5G>A_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Based_on_currently_available_evidence,_it_is_unclear_whether_FANCC_c.843+5G>A_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Insufficient_evidence:RNA_Studies
NM_000051.3:c.5763-1050A>G	ATM	intron_variant	47092	3	15426	2	-	-	-	-	3021	18060	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_variant|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1876175,Orphanet:ORPHA370109|MedGen:CN517202	-	NC_000011.9:g.108179837A>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:607585.0004	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	774925473	-	Eurofins_Clinical_Diagnostics	Pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Uncertain_significance|Pathogenic	2004-06-01|2018-12-23|2016-10-27|2016-01-05|2019-06-20|2018-08-16|2016-12-12	2015-07-16|2019-03-28|2016-10-27|2016-11-23|2020-02-26|2018-11-06|2018-09-19	no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|unknown|germline|germline|germline	SCV000023315|SCV000282999|SCV000328266|SCV000485197|SCV000581456|SCV000902857|SCV000700719	Ataxia-telangiectasia_variant|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	|This_sequence_change_falls_in_intron_38_of_the_ATM_mRNA._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_ATM_protein._This_variant_is_not_present_in_population_databases_(rs774925473,_ExAC_no_frequency)._This_variant_has_been_reported_in_several_individuals_affected_with_atypical_ataxia-telangiectasia_(characterized_by_later_disease_onset_and/or_slower_disease_progression_and_attenuated_disease_features_than_classical_ataxia-telangiectasia)_(PMID:_8755918,_21792198,_10330348,_8808599)._Notably,_one_individual_carried_this_variant_in_trans_with_a_second_pathogenic_variant,_c.9139C>T_(p.Arg3047*),_and_two_affected_brothers_have_been_reported_to_be_homozygous_for_this_variant_(PMID:_10234507,_15174027)._This_variant_is_also_known_as_5762ins137,_the_4-1-8_variant,_IVS40-1050A>G,_IVS40+1126A>G,_IVS40ins137,_and_5763ins130_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_3021)._Experimental_studies_have_shown_that_this_intronic_change_results_in_the_insertion_of_part_of_intron_38_in_between_exons_38_and_39,_resulting_in_a_frameshift_(PMID:_8755918,_19823873)._However,_this_variant_is_described_as_a_leaky_splice_site_mutation,_as_only_a_portion_of_the_transcripts_from_this_allele_contain_this_insertion,_as_shown_by_cDNA_sequencing_(PMID:_8755918)._The_remaining_transcripts_expressed_from_this_allele_result_in_low-level_expression_of_ATM_protein_with_near_wild-type_levels_of_kinase_activity_(PMID:_11382771,_25040471)._These_results_may_explain_the_atypical_disease_associated_with_this_variant._For_these_reasons,_this_variant_has_been_classified_as_Pathogenic.|||Functionally-validated_splicing_mutation:Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Other_strong_data_supporting_pathogenic_classification||
NM_000051.3:c.5821G>C	ATM	missense_variant	102512	27	15418	3	-	-	-	-	127412	132869	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN517202	-	NC_000011.9:g.108180945G>C	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(11)	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	147187700	-	Ambry_Genetics|Color|Academic_Department_of_Medical_Genetics,_University_of_Cambridge|Invitae|Counsyl|Mendelics|GeneDx|Center_for_Pediatric_Genomic_Medicine,Children's_Mercy_Hospital_and_Clinics|Athena_Diagnostics_Inc|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America	Uncertain_significance|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_Significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2018-12-03|2018-09-11|2018-01-26|2018-12-23|2017-11-10|2018-07-02|2018-12-10|2016-01-18|2018-03-21|2018-09-01|2017-05-23|2019-07-10	2020-02-26|2018-11-06|2018-04-23|2019-03-28|2018-07-10|2018-08-20|2019-01-29|2016-05-19|2018-08-31|2019-07-12|2017-05-23|2019-09-24	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|unknown|germline	SCV000184428|SCV000537538|SCV000992202|SCV000218522|SCV000795616|SCV000838559|SCV000149126|SCV000280993|SCV000840946|SCV001148436|SCV000611367|SCV000918576	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|not_provided|not_provided|Familial_cancer_of_breast/Ataxia-telangiectasia_syndrome|not_specified	Insufficient_evidence||Application_of_AMCG_guidelines_2015._Used_other_ClinVar_submission_evidence_where_relevant._Loss_of_heterozygosity_in_tumours_or_immunohistochemistry_abnormalities_considered_functional_evidence_of_pathogenicity.|This_sequence_change_replaces_valine_with_leucine_at_codon_1941_of_the_ATM_protein_(p.Val1941Leu)._The_valine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_valine_and_leucine._This_variant_is_present_in_population_databases_(rs147187700,_ExAC_0.02%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_19781682,_16832357,_25503501),_chronic_lymphocytic_leukemia_(PMID:_21933854),_and_suspected_Lynch_syndrome_(PMID:_25980754)._However,_in_aÂ¬â€ large_meta-analysis_this_variant_was_not_associated_with_an_increased_risk_of_breast_cancer_(PMID:_19781682).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127412)._Experimental_studies_have_shown_that_this_missense_change_leads_to_reduced_ATM_kinase_activity_(PMID:_19431188)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||This_variant_is_denoted_ATM_c.5821G>C_at_the_cDNA_level,_p.Val1941Leu_(V1941L)_at_the_protein_level,_and_results_in_the_change_of_a_Valine_to_a_Leucine_(GTT>CTT)._ATM_Val1941Leu_has_been_reported_in_individuals_with_breast_cancer,_glioma,_or_a_Lynch_related-cancer_and/or_polyps_undergoing_multigene_hereditary_cancer_testing_(Maxwell_2015,_Tung_2015,_Yurgelun_2015,_Zhang_2015,_Hauke_2018),_and_on_functional_interrogation,_demonstrated_reduced_ATM_protein_level_and_kinase_activity_(Barone_2009)._However,_in_two_large_case-control_studies_ATM_Val1941Leu_was_present_at_similar_or_lower_frequencies_in_breast_cancer_patients_compared_to_control_subjects_(Tavtigian_2009,_Decker_2017)._In_addition,_this_variant_was_present_at_similar_or_lower_frequencies_in_cases_vs._controls_in_two_chronic_lymphocytic_leukemia_case-control_studies_(Skowronska_2012,_Tiao_2017)._ATM_Val1941Leu_was_observed_at_an_allele_frequency_of_0.02%_(29/126,446)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_not_located_in_a_known_functional_domain._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_that_this_variant_does_not_alter_protein_structure/function._Based_on_currently_available_evidence,_it_is_unclear_whether_ATM_Val1941Leu_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|Converted_during_submission_to_Uncertain_significance.||||Variant_summary:_ATM_c.5821G>C_(p.Val1941Leu)_results_in_a_conservative_amino_acid_change_in_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_benign_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_0.00013_in_251056_control_chromosomes,_predominantly_at_a_frequency_of_0.00026_within_the_Non-Finnish_European_subpopulation_in_the_gnomAD_database._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_ATM_causing_Breast_Cancer_(0.00013_vs_0.001),_allowing_no_conclusion_about_variant_significance._However,_the_variant_was_also_reported_in_10_/_9884_women_(i.e._with_a_frequency_of_about_0.001),_who_were_older_than_70_years_of_age,_and_never_had_cancer_(FLOSSIES_database),_which_might_suggest_a_benign_outcome_for_the_variant._c.5821G>C_has_been_reported_in_the_literature_in_individuals_affected_with_Breast_Cancer_(Shayeghi_1998,_Renwick_2006,_Maxwell_2015)_,_other_tumor_phenotypes_such_as_chronic_lymphocytic_leukemia_(CLL),_Lynch_syndrome-associated_cancer_and/or_polyps_,_pediatric_low_grade_glioma_(Skowronska_2011,_Yurgelun_2015,_Zhang_2015,_Tung_2015)_and_also_in_several_healthy_controls_(Skowronska_2011,_Tiao_2017,_Tavtigian_2009)._These_reports_therefore_do_not_provide_unequivocal_conclusions_about_association_of_the_variant_with_Breast_Cancer._Co-occurrence_with_another_pathogenic_variant_has_been_reported_for_this_variant_(BRCA1_c.3607C>T,_p.Arg1203X,_internal_sample),_which_further_supports_its_role_as_a_benign_variant._Using_an_ATM-null_lymphoblastoid_cell_line_(LCL)_transfected_with_the_variant_of_interest,_Barone_et_al_demonstrated_an_approximately_50%_decrease_in_protein_expression_(or_stability)_but_no_significant_decrease_in_specific_kinase_activity_(Barone_2009)._Nine_ClinVar_submissions_(evaluation_after_2014)_cite_the_variant_as_uncertain_significance._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_uncertain_significance.
NM_000051.3:c.6154G>A	ATM	missense_variant	102702	1	15424	1	4&4	1&1	rs202206540	Hereditary cancer-predisposing syndrome&Ataxia-telangiectasia syndrome	181975	180484	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108186796G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(3),Pathogenic(1),Uncertain_significance(2)	-	single_nucleotide_variant	SO:0001483	-	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	17	202206540	-	Klinikum_rechts_der_Isar|Baylor_Genetics|GeneDx	Likely_pathogenic|Uncertain_significance|Uncertain_significance|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic	2019-08-15|2018-08-06|2018-12-28|2016-10-27|2019-06-13|0000-00-00|2018-10-08	2020-02-26|2018-11-06|2019-03-28|2016-10-27|2020-01-21|2019-09-27|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|maternal|germline|germline	SCV000216022|SCV000911078|SCV000218611|SCV000328267|SCV001150023|SCV001163272|SCV000209758	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Moderate_segregation_with_disease_(at_least_3_informative_meioses)_for_rare_diseases.:Deficient_protein_function_in_appropriate_functional_assay(s):Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation||This_sequence_change_replaces_glutamic_acid_with_lysine_at_codon_2052_of_the_ATM_protein_(p.Glu2052Lys)._The_glutamic_acid_residue_is_moderately_conserved_and_there_is_a_small_physicochemical_difference_between_glutamic_acid_and_lysine._This_variant_is_present_in_population_databases_(rs202206540,_ExAC_0.03%)._This_variant_has_been_reported_to_segregate_in_one_family_with_dopa-responsive_dystonia_in_individuals_who_also_carry_a_loss-of-function_variant_(c.7886_7890del)Â¬â€ on_the_opposite_chromosome_(in_trans)Â¬â€ in_the_ATM_gene._One_family_member_who_presented_with_typical_manifestations_of_ataxia-telangiectasia_(A-T)_was_homozygous_for_the_c.7886_7890del_variant_and_did_not_carry_the_p.Glu2052Lys_variant_(PMID:_23946315)._This_variant_was_also_found_to_be_homozygous_in_an_individual_with_A-T,_and_heterozygous_in_several_individuals_with_breast_cancer_(PMID:_10330348,_27616075,Â¬â€ 29470806)._However,_it_has_also_been_observed_in_trans_with_a_pathogenic_variant_in_ATM_in_an_individual_not_affected_with_A-T,_indicating_that_this_variant_might_not_be_causative_of_disease_(Invitae).Â¬â€ ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_181975)._An_experimental_study_using_a_lymphoblastoid_cell_line_derived_from_an_A-T_affected_individual_has_shown_that_this_missense_change_can_produce_a_defect_in_RNA_splicing_and_loss_of_ATM_protein_(PMID:_10330348)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.||||This_variant_is_denoted_ATM_c.6154G>A_at_the_cDNA_level,_p.Glu2052Lys_(E2052K)_at_the_protein_level,_and_results_in_the_change_of_a_Glutamic_Acid_to_a_Lysine_(GAA>AAA)._This_variant_was_observed_in_the_homozygous_state_in_an_individual_with_ataxia_telangiectasia,_and_cDNA_derived_from_this_patient_was_identified_to_have_ATM_transcripts_with_exon_42_deleted,_also_known_as_exon_44_using_alternate_nomenclature,_and_absence_of_ATM_protein_by_Western_blot_(Teraoka_1999)._Although_ATM_Glu2052Lys_is_not_predicted_to_affect_splicing_by_published_and_internal_splicing_models,_authors_suggest_that_this_variant_may_alter_the_secondary_structure_of_the_transcript,_which_may_disrupt_the_formation_of_the_spliceosome_(Teraoka_1999)._This_variant_was_also_identified_in_trans_with_an_ATM_frameshift_variant_in_multiple_members_of_a_family_affected_with_cervical_dopa-responsive_dystonia,_elevated_AFP,_and_telangiectasias_(Charlesworth_2013),_as_well_as_in_an_individual_with_bilateral_breast_cancer_and_a_family_history_of_pancreatic_cancer_(Kraus_2017)._ATM_Glu2052Lys_was_observed_at_an_allele_frequency_of_0.03%_(5/16476)_in_individuals_of_South_Asian_ancestry_in_large_population_cohorts_(Lek_2016)._ATM_Glu2052Lys_is_located_in_the_FAT_domain_(Stracker_2013)._Based_on_the_currently_available_evidence,_we_consider_ATM_Glu2052Lys_to_be_a_likely_pathogenic_variant.
NM_000051.3:c.7328G>A	ATM	missense_variant	102486	1	15432	1	-	-	-	-	142211	151925	Ataxia-telangiectasia_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN517202	-	NC_000011.9:g.108200961G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_041577	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	1	587782310	-	Ambry_Genetics|Color|Invitae|GeneDx	Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2019-04-25|2018-06-16|2018-11-07|2018-08-09	2020-02-26|2018-11-06|2019-03-28|2019-01-29	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline	SCV000186153|SCV000682405|SCV000283048|SCV000292481	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|not_provided	Insufficient_evidence||This_sequence_change_replaces_arginine_with_glutamine_at_codon_2443_of_the_ATM_protein_(p.Arg2443Gln)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_glutamine._This_variant_is_present_in_population_databases_(rs587782310,_ExAC_0.006%)._This_variant_has_been_observed_in_an_individual_affected_with_multiple_cancers,_including_colon,_prostate,_multiple_myeloma,_melanoma_and_brain_(Invitae)._However,_in_that_individual,_a_pathogenic_allele_was_also_identified_in_ATM,_which_suggests_that_this_c.7328G>A_variant_was_not_the_primary_cause_of_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_142211)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_do_not_agree_on_the_potential_impact_of_this_missense_change_(SIFT:_Deleterious:_PolyPhen-2:_Probably_Damaging:_Align-GVGD:_Class_C0)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|This_variant_is_denoted_ATM_c.7328G>A_at_the_cDNA_level,_p.Arg2443Gln_(R2443Q)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Glutamine_(CGA>CAA)._This_variant_has_been_identified_in_at_least_one_breast_cancer_patient_(Hauke_2018),_and_has_been_observed_internally_in_the_compound_heterozygous_state_in_two_individuals_with_features_consistent_with_atypical_ataxia-telangiectasia._Additionally,_it_has_been_reported_as_a_somatic_variant_in_lymphoma,_breast,_colorectal,_and_other_tumor_specimens_(Greiner_2006,_Yip_2012,_Balko_2014,_Giannakis_2014)._ATM_Arg2443Gln_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._Since_Arginine_and_Glutamine_differ_in_some_properties,_this_is_considered_a_semi-conservative_amino_acid_substitution._ATM_Arg2443Gln_is_located_in_the_FAT_domain_(Stracker_2013)._In_silico_analyses_including_protein_predictors_and_evolutionary_conservation,_support_that_this_variant_does_not_alter_protein_structure/function._Based_on_currently_available_evidence_and_internal_data,_we_consider_ATM_Arg2443Gln_to_be_a_likely_pathogenic_variant.
NM_000051.3:c.7475T>G	ATM	missense_variant	102574	19	15430	7	-	-	-	-	127446	132903	Ataxia-telangiectasia_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_specified|not_provided	-	MedGen:C0004135,OMIM:208900,Orphanet:ORPHA100,SNOMED_CT:68504005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN517202	-	NC_000011.9:g.108201108T>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(12)	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):Q13315#VAR_041579|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2219360	-	ATM:472|C11orf65:160140	SO:0001627|intron_variant	5	56399857	-	Ambry_Genetics|Color|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|GeneKor_MSA|Invitae|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|Counsyl|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|GeneDx|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|EGL_Genetic_Diagnostics,Eurofins_Clinical_Diagnostics|Integrated_Genetics/Laboratory_Corporation_of_America|Clinical_Cancer_Genetics_and_Family_Consultants,Athens_Medical_Center	Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2019-06-06|2018-05-09|2017-07-12|2018-08-01|2018-12-29|0000-00-00|2017-05-31|2018-05-24|2019-01-25|2018-09-04|2019-05-01|2017-02-21|2018-10-19|2019-06-27	2020-02-26|2018-11-06|2017-08-08|2018-08-08|2019-03-28|2018-04-04|2018-04-09|2018-07-10|2019-08-05|2019-01-29|2019-07-12|2018-09-19|2019-04-24|2019-06-28	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|germline|germline|germline|inherited	SCV000172858|SCV000537541|SCV000679694|SCV000821871|SCV000254145|SCV000732995|SCV000745132|SCV000800168|SCV001160197|SCV000149161|SCV000574909|SCV000706050|SCV000918571|SCV000924666	Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|Ataxia-telangiectasia_syndrome|not_provided|not_provided|not_provided|not_specified|Familial_cancer_of_breast	Insufficient_evidence||||This_sequence_change_replaces_leucine_with_arginine_at_codon_2492_of_the_ATM_protein_(p.Leu2492Arg)._The_leucine_residue_is_moderately_conserved_and_there_is_a_moderate_physicochemical_difference_between_leucine_and_arginine._This_variant_is_present_in_population_databases_(rs56399857,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_affected_with_chronic_lymphocytic_leukemia_(PMID:_28652578),_suspected_Lynch_syndrome_(PMID:_25980754),_glioblastoma_(PMID:_26689913),_and_breast_cancer_(Invitae)._However,_in_the_latter_individual_a_pathogenic_allele_was_also_identified_in_ATM,_which_suggests_that_this_c.7475T>G_variant_was_not_the_primary_cause_of_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_127446)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_(SIFT,_PolyPhen-2,_Align-GVGD)_all_suggest_that_this_variant_is_likely_to_be_disruptive,_but_these_predictions_have_not_been_confirmed_by_published_functional_studies._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.||||The_ATM_c.7475T>G:_p.Leu2492Arg_variant_(rs56399857)_is_reported_in_the_literature_in_individuals_with_colorectal_cancer_(Yurgelun_2017),_chronic_lymphocytic_leukemia_(Tiao_2017),_and_glioblastoma_multiforme_(Lu_2015)._This_variant_is_reported_with_uncertain_significance_by_multiple_laboratories_in_ClinVar_(Variation_ID:_127446)._It_is_found_in_the_general_population_with_an_overall_allele_frequency_of_0.01%_(32/282684_alleles)_in_the_Genome_Aggregation_Database._The_leucine_at_codon_2492_is_highly_conserved_and_computational_analyses_(SIFT,_PolyPhen-2)_predict_that_this_variant_is_deleterious._Due_to_limited_information,_the_clinical_significance_of_this_variant_is_uncertain_at_this_time._REFERENCES_Lu_C_et_al._Patterns_and_functional_implications_of_rare_germline_variants_across_12_cancer_types._Nat_Commun._2015_Dec_22:6:10086._Tiao_G_et_al._Rare_germline_variants_in_ATM_are_associated_with_chronic_lymphocytic_leukemia._Leukemia._2017_Oct:31(10):2244-2247._Yurgelun_MB_et_al._Cancer_Susceptibility_Gene_Mutations_in_Individuals_With_Colorectal_Cancer._J_Clin_Oncol._2017_Apr_1:35(10):1086-1095.|This_variant_is_denoted_ATM_c.7475T>G_at_the_cDNA_level,_p.Leu2492Arg_(L2492R)_at_the_protein_level,_and_results_in_the_change_of_a_Leucine_to_an_Arginine_(CTT>CGT)._This_variant_has_been_observed_in_individuals_with_breast_cancer_(Decker_2017,_Hauke_2018),_colon_cancer_(Yurgelun_2017),_and_other_cancers_(Greenman_2007,_Lu_2015,_Tiao_2017,_Yehia_2018)._ATM_Leu2492Arg_was_observed_at_an_allele_frequency_of_0.02%_(27/126,540)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._ATM_Leu2492Arg_is_located_within_the_FAT_domain_(Stracker_2013)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_support_a_deleterious_effect._Based_on_currently_available_evidence,_it_is_unclear_whether_ATM_Leu2492Arg_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|||Variant_summary:_ATM_c.7475T>G_(p.Leu2492Arg)_results_in_a_non-conservative_amino_acid_change_located_in_the_PIK-related_kinase,_FAT_domain_(IPR003151)_of_the_encoded_protein_sequence._Five_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_0.0001_in_277034_control_chromosomes_(gnomAD)._This_frequency_is_not_higher_than_expected_for_a_pathogenic_variant_in_ATM_causing_Ataxia-Telangiectasia_(0.0001_vs_0.004),_allowing_no_conclusion_about_variant_significance._In_addition,_the_variant_was_found_in_5/7325_European_American_women,_who_were_older_than_70_years_of_age,_and_never_had_cancer_(in_the_FLOSSIES_database)._c.7475T>G_has_been_reported_in_the_literature_in_individuals_affected_with_lung_cancer,_glioblastoma,_leukemia,_breast_cancer,_and_Lynch_syndrome_associated_cancers,_and_also_in_healthy_controls_(Bernstein_2010,_Greenman_2007,_Lu_2015,_Tiao_2017,_Young_2016,_Yurgelun_2015,_Yurgelun_2017)._These_reports_do_not_provide_unequivocal_conclusions_about_association_of_the_variant_with_Ataxia-Telangiectasia._To_our_knowledge,_no_experimental_evidence_demonstrating_an_impact_on_protein_function_has_been_reported._Ten_clinical_diagnostic_laboratories_have_submitted_clinical-significance_assessments_for_this_variant_to_ClinVar_after_2014_without_evidence_for_independent_evaluation._All_laboratories_classified_the_variant_as_uncertain_significance._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_uncertain_significance.|This_variant_is_denoted_ATM_c.7475T>G_at_the_cDNA_level,_p.Leu2492Arg_at_the_protein_level,_and_is_a_non-conservative_amino_acid_change_located_in_the_PIK-related_kinase,_FAT_domain_(Stracker_2013)_of_the_encoded_protein_sequence._Five_of_five_in_silico_tools_predict_a_damaging_effect_of_this_variant_on_protein_function._This_is_a_rare_variant_(ExAC_0.00006),_and_has_been_reported_in_various_cancers_(Lu_2015,_Greenman_2007,_Berstein_2010)._We_report_this_variant_to_occur_in_two_sisters,_both_heterozygotes,_with_breast_cancer,_of_47_and_50_years_old._The_second_one_also_developed_thyroid_cancer_at_the_age_of_55._A_third_sister_tested,_is_a_healthy_non-carrier_at_the_age_of_59_years_old._The_family_on_the_paternal_side_included_one_case_of_breast_cancer_at_the_age_of_70_years_old,_and_another_one_with_breast_and_thyroid_cancer_at_the_age_of_40_and_65_years_old_respectively._For_these_reasons,_this_variant_may_be_causative_of_disease_in_this_family_and_we_classify_it_as_probably_pathogenic.
NM_000059.3:c.831T>G	BRCA2	missense_variant	100898	14	15414	1	3	1	rs28897705	Hereditary cancer-predisposing syndrome	38152	46708	_familial_2|not_specified|Breast_and/or_ovarian_cancer|not_provided	-	MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2675520,OMIM:612555|MedGen:CN169374|MedGen:CN221562|MedGen:CN517202	-	NC_000013.10:g.32906446T>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Benign(1),Likely_benign(7),Likely_pathogenic(1),Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	-	-	BRCA2:675	SO:0001583|missense_variant	1	28897705	-	Sharing_Clinical_Reports_Project_(SCRP)|Breast_Cancer_Information_Core_(BIC)_(BRCA2)|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Diagnostic_Laboratory,_Department_of_Genetics,University_Medical_Center_Groningen|Genome_Diagnostics_Laboratory,University_Medical_Center_Utrecht|DNA_and_Cytogenetics_Diagnostics_Unit,Erasmus_Medical_Center|GeneDx|Laboratory_for_Molecular_Medicine,_Partners_HealthCare_Personalized_Medicine|Department_of_Pathology_and_Laboratory_Medicine,Sinai_Health_System|Ambry_Genetics|Color|Invitae|Integrated_Genetics/Laboratory_Corporation_of_America|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|CHEO_Genetics_Diagnostic_Laboratory,Children's_Hospital_of_Eastern_Ontario	Benign|Uncertain_significance|Benign|Likely_benign|Likely_benign|Likely_benign|Likely_benign|Uncertain_significance|Uncertain_significance|Likely_benign|Likely_benign|Likely_benign|Likely_benign|Likely_pathogenic|Uncertain_significance	2009-06-16|2002-05-29|2014-11-03|0000-00-00|2017-07-28|2015-09-21|2017-11-01|2016-10-20|2015-06-30|2018-06-25|2016-01-13|2019-02-11|2017-07-10|2017-08-01|2017-02-10	2012-07-24|2014-03-28|2016-04-21|2018-04-04|2018-04-17|2018-04-09|2018-03-26|2017-04-03|2017-04-19|2020-02-26|2018-11-06|2019-03-14|2018-01-25|2019-07-12|2018-04-30	no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000054342|SCV000145776|SCV000195953|SCV000733218|SCV000743251|SCV000744394|SCV000210256|SCV000538502|SCV000591715|SCV000185184|SCV000910741|SCV000073484|SCV000695142|SCV001148970|SCV000901094	Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|Breast-ovarian_cancer,_familial_2|not_specified|not_specified|not_specified|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_provided|not_provided|not_provided|Breast_and/or_ovarian_cancer	||||||This_variant_is_considered_likely_benign_or_benign_based_on_one_or_more_of_the_following_criteria:_it_is_a_conservative_change,_it_occurs_at_a_poorly_conserved_position_in_the_protein,_it_is_predicted_to_be_benign_by_multiple_in_silico_algorithms,_and/or_has_population_frequency_not_consistent_with_disease.|Variant_identified_in_a_genome_or_exome_case(s)_and_assessed_due_to_predicted_null_impact_of_the_variant_or_pathogenic_assertions_in_the_literature_or_databases._Disclaimer:_This_variant_has_not_undergone_full_assessment._The_following_are_preliminary_notes:_1_report_identified_this_varint_in_a_prostate_cancer_cohort_-_reported_as_unclassified_variant:_ClinVar:_3_VUS,_2_LB/B||Other_data_supporting_benign_classification:Co-occurence_with_mutation_in_same_gene_(phase_unknown):In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species|||||
NM_024675.3:c.3428T>A	PALB2	missense_variant	102740	29	15436	3	-	-	-	-	126740	132250	_complementation_group_N|Pancreatic_cancer_3|bilateral_breast_cancer|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1835817,OMIM:610832|MedGen:C3150547,OMIM:613348|MedGen:CN235586|MedGen:CN517202	-	NC_000016.9:g.23614913A>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(9)	-	single_nucleotide_variant	SO:0001483	-	-	PALB2:79728	SO:0001583|missense_variant	1	62625284	-	Invitae|Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|Counsyl|Ambry_Genetics|Mendelics|Color|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Fulgent_Genetics,Fulgent_Genetics|Center_of_Medical_Genetics_and_Primary_Health_Care	Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_benign|Uncertain_significance|Likely_benign|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2018-12-27|2015-06-01|2015-11-26|2018-12-18|2018-07-02|2016-05-06|2018-12-27|2016-06-10|2016-02-05|2019-02-03|2018-10-31|0000-00-00	2019-03-28|2015-08-13|2016-11-23|2020-02-26|2018-08-20|2018-11-06|2019-01-29|2018-01-25|2018-01-29|2020-03-06|2018-11-14|2019-08-31	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|unknown|germline|unknown|germline|germline|germline|germline|germline|unknown|germline	SCV000166662|SCV000268028|SCV000487859|SCV000186860|SCV000838993|SCV000902660|SCV000150013|SCV000699596|SCV000807109|SCV000888376|SCV000894995|SCV000987257	_complementation_group_N/Pancreatic_cancer_3|bilateral_breast_cancer	This_sequence_change_replaces_leucine_with_histidine_at_codon_1143_of_the_PALB2_protein_(p.Leu1143His)._The_leucine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_leucine_and_histidine._This_variant_is_present_in_population_databases_(rs62625284,_ExAC_0.03%),_and_has_an_allele_count_higher_than_expected_for_a_pathogenic_variant_(PMID:_28166811)._This_variant_has_been_reported_in_individuals_affected_with_breast,_ovarian_and_pancreatic_cancer,_as_well_as_in_unaffected_individuals_(PMID:_20852946,_22692731,_24556926,_26283626,_25186627,_25479140,_26315354,_27878467)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126740)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_do_not_agree_on_the_potential_impact_of_this_missense_change_(SIFT:_Tolerated:_PolyPhen-2:_Probably_Damaging:_Align-GVGD:_Class_C0)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||Insufficient_or_conflicting_evidence:No_disease_association_in_appropriately_sized_case-control_study(ies)|||This_variant_is_denoted_PALB2_c.3428T>A_at_the_cDNA_level,_p.Leu1143His_(L1143H)_at_the_protein_level,_and_results_in_the_change_of_a_Leucine_to_a_Histidine_(CTT>CAT)._This_variant_has_been_observed_in_multiple_individuals_with_breast,_ovarian,_or_pancreatic_cancer,_but_has_also_been_observed_in_control_subjects_(Balia_2010,_Catucci_2012,_Catucci_2014,_Kanchi_2014,_Damiola_2015,_Grant_2015,_Lu_2015,_Ramus_2015,_Thompson_2015,_Tung_2015,_Caminsky_2016,_Hauke_2018)._PALB2_Leu1143His_was_observed_at_an_allele_frequency_of_0.025%_(32/126,718)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_WD6_repeat_region,_the_region_required_for_POLH_DNA_synthesis_stimulation,_as_well_as_the_region_of_interaction_with_RAD51,_BRCA2_and_POLH_(Oliver_2009,_Buisson_2010,_Buisson_2014,_UniProt)._In_silico_analyses,_including_protein_predictors_and_evolutionary_conservation,_support_a_deleterious_effect._Based_on_currently_available_evidence,_it_is_unclear_whether_PALB2_Leu1143His_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|Variant_summary:_The_PALB2_c.3428T>A_(p.Leu1143His)_variant_involves_the_alteration_of_a_conserved_nucleotide_and_results_in_a_replacement_of_a_medium_size_and_hydrophobic_Leucine_(L)_with_a_medium_size_and_polar_Histidine_(H)_located_in_PALB2_WD40_domain,_which_is_interacting_with_BRCA2_(PMID:21618343)._4/5_in_silico_tools_predict_a_damaging_outcome._This_variant_was_found_in_25/126456_control_chromosomes,_predominantly_observed_in_the_European_(Non-Finnish)_subpopulation_at_a_frequency_of_0.0003149_(21/66678)._This_frequency_is_about_2_times_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_PALB2_variant_(0.0001563),_suggesting_the_variant_to_be_in_the_neutral_spectrum._It_was_reported_in_several_HBOC_patients,_however_without_strong_evidence_for_pathogenicity_such_as_co-segregation_information._Another_variant_affecting_the_same_codon,_p.Leu1143Pro_have_been_observed_in_a_patient_with_bilateral_breast_cancer_shown_to_disrupt_the_PALB2-RAD51C-BRCA2_complex_indicating_the_functional_importance_of_the_Leu1143_residue_(PMID:24141787,_PMID:21618343)._Multiple_clinical_diagnostic_laboratories_classified_this_variant_as_VUS._Taken_together,_this_variant_is_classified_as_variant_of_uncertain_significance_until_more_information_becomes_available.||||
NM_024675.3:c.2674G>A	PALB2	missense_variant	102748	15	15430	1	-	-	-	-	126672	132182	Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|not_specified|PALB2-Related_Disorders|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:CN169374|MedGen:CN239408|MedGen:CN517202	-	NC_000016.9:g.23637631C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(8)	-	single_nucleotide_variant	SO:0001483	Illumina:820015	-	PALB2:79728	SO:0001583|missense_variant	1	45476495	-	Invitae|Cancer_Genetics_Laboratory,Peter_MacCallum_Cancer_Centre|Counsyl|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America|Illumina_Clinical_Services_Laboratory,Illumina	Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2019-01-11|2015-06-01|2018-01-30|2019-01-30|2018-08-08|2017-03-06|2019-01-07|2016-09-16|2017-04-28	2019-03-28|2015-08-13|2018-06-20|2020-02-26|2018-11-06|2017-08-01|2019-01-29|2018-01-25|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|unknown|germline|germline|germline|germline|germline|germline	SCV000260420|SCV000268016|SCV000785999|SCV000186221|SCV000685968|SCV000601768|SCV000566596|SCV000699574|SCV000914712	Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_provided|not_provided|PALB2-Related_Disorders	This_sequence_change_replaces_glutamic_acid_with_lysine_at_codon_892_of_the_PALB2_protein_(p.Glu892Lys)._The_glutamic_acid_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_glutamic_acid_and_lysine._This_variant_is_present_in_population_databases_(rs45476495,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_affected_with_breast_and_pancreatic_cancer_(PMID:_17200668,_26283626,_22241545,_25356972,_26534844,_28503720),_stomach_adenocarcinoma,_lung_squamous_cell_carcinomaÂ¬â€ (PMID:Â¬â€ 26689913),_prostate_cancer_(PMID:_29368341),_and_an_individual_with_suspected_Lynch_syndrome_(PMID:_25980754)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_126672)._Algorithms_developed_to_predict_the_effect_of_missense_changes_on_protein_structure_and_function_do_not_agree_on_the_potential_impact_of_this_missense_change_(SIFT:_Deleterious:_PolyPhen-2:_Probably_Damaging:_Align-GVGD:_Class_C15)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||Insufficient_or_conflicting_evidence:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Rare_(0.1%)_in_general_population_databases_(dbsnp,_esp,_1000_genomes)_:Conflicting_evidence|||This_variant_is_denoted_PALB2_c.2674G>A_at_the_cDNA_level,_p.Glu892Lys_(E892K)_at_the_protein_level,_and_results_in_the_change_of_a_Glutamic_Acid_to_a_Lysine_(GAA>AAA)._This_variant_has_been_observed_in_a_family_with_at_least_two_cases_of_pancreatic_cancer_(Zhen_2015),_in_an_individual_with_a_Lynch_syndrome_associated_cancer_and/or_polyps_(Yurgelun_2015),_and_in_multiple_individuals_with_a_personal_and/or_family_history_of_breast_and/or_ovarian_cancer_(Rahman_2007,_Tischkowitz_2012,_Nguyen-Dumont_2015,_Ramus_2015,_Thompson_2015,_Tung_2015,_Li_2016,_Decker_2017,_Rummel_2017):_however,_it_has_also_been_observed_in_at_least_one_control_population_(Decker_2017)._PALB2_Glu892Lys_was_observed_at_an_allele_frequency_of_0.01%_in_individuals_of_European_(Non-Finnish)_ancestry_in_large_population_cohorts_(Lek_2016)._PALB2_Glu892Lys_is_located_within_the_first_WD_repeat,_the_region_of_interaction_with_RAD51,_BRCA2_and_POLH,_and_the_region_required_for_POLH_DNA_synthesis_stimulation_(Oliver_2009,_Buisson_2010,_Buisson_2014,_UniProt)._In-silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_it_is_unclear_whether_PALB2_Glu892Lys_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|Variant_summary:_The_PALB2_c.2674G>A_(p.Glu892Lys)_variant_involves_the_alteration_of_a_conserved_nucleotide_and_is_located_at_WD40_domain_of_the_PALP2_protein._2/3_in_silico_tools_predict_a_damaging_outcome_for_this_variant._This_variant_was_found_in_8/123578_control_chromosomes_at_a_frequency_of_0.0000647,_which_does_not_exceed_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_PALB2_variant_(0.0001563)._In_literature,_this_variant_has_been_reported_in_several_cancer_patients_(Rahman_2007,_Tischkowitz_2012,_Li_2016,_Nguyen-Dumont_2015,_Thompson_2015,_Zhen_2015),_primarily_patients_with_breast_and/or_ovarian_cancer._However,_no_strong_evidences_(such_as_co-segregation_with_disease)_supporting_the_pathogenicity_were_reported._In_addition,_there_are_no_case-control_studies_that_provide_information_whether_or_not_it_could_elevate_the_risk_of_cancer,_especially_breast_cancer._There_are_no_published_functional_studies_for_the_variant._Multiple_clinical_diagnostic_laboratories_have_classified_this_variant_as_uncertain_significance._Taken_together,_this_variant_is_currently_classified_as_Variant_of_Uncertain_Significance.|The_PALB2_c.2674G>A_(p.Glu892Lys)_variant_has_been_reported_in_five_studies_in_which_it_is_found_in_a_heterozygous_state_in_eight_individuals_with_breast_cancer_who_previously_tested_negative_for_variants_in_the_BRCA1_and_BRCA2_genes_(Rahman_et_al._2007:_Tischkowitz_et_al._2012:_Thompson_et_al._2015:_Nguyen-Dumont_et_al._2015)_and_in_one_breast_cancer_family_(Li_et_al._2016)._The_p.Glu892Lys_variant_has_also_been_found_in_a_heterozygous_state_in_one_individual_with_pancreatic_cancer_(Zhen_et_al._2015)_and_in_a_patient_with_Lynch_syndrome_who_was_also_heterozygous_for_a_missense_variant_in_the_MUTYH_gene_(Yurgelun_et_al._2015)._The_p.Glu892Lys_variant_was_not_found_in_at_least_3600_control_individuals_but_is_reported_at_a_frequency_of_0.00012_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Although_this_variant_has_not_been_reported_in_any_probands_with_Fanconi_anemia,_it_is_known_that_PALB2_heterozygous_variants_can_also_confer_carrier_status_for_Fanconi_anemia._Based_on_the_available_evidence,_the_p.Glu892Lys_variant_is_classified_as_likely_pathogenic_for_PALB2-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_007294.3:c.5407-25T>A	BRCA1	intron_variant	102710	1	15424	1	-	-	-	-	371817	358928	_familial_1|not_specified	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374	-	NC_000017.10:g.41199745A>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(2)	-	single_nucleotide_variant	SO:0001483	-	-	BRCA1:672	SO:0001627|intron_variant	1	758780152	-	Counsyl|Research_Molecular_Genetics_Laboratory,Women's_College_Hospital,_University_of_Toronto|Invitae|Ambry_Genetics	Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2016-02-19|2014-01-31|2018-12-18|2019-09-25	2016-11-23|2017-08-04|2019-03-28|2020-02-26	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter	unknown|germline|germline|germline	SCV000488207|SCV000587505|SCV000636038|SCV001186006	_familial_1|not_specified|Hereditary_breast_and_ovarian_cancer_syndrome|Hereditary_cancer-predisposing_syndrome	||This_sequence_change_falls_in_intron_21_of_the_BRCA1_gene._It_does_not_directly_change_the_encoded_amino_acid_sequence_of_the_BRCA1_protein._This_variant_is_not_present_in_population_databases_(ExAC_no_frequency)._This_variant_has_been_reported_in_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_12774040,_24010542,_26350514)._This_variant_is_also_known_as_IVS22-25T>A_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_371817)._Algorithms_developed_to_predict_the_effect_of_sequence_changes_on_RNA_splicing_suggest_that_this_variant_may_alter_RNA_splicing._This_variant_has_been_reported_to_result_in_a_transcript_with_partial_loss_of_exon_23,_but_the_details_of_these_studies_are_not_available_in_published_literature_(PMID:_26350514,_LOVD)._In_summary,_this_is_a_rare_intronic_change_with_uncertain_impact_on_splicing._It_has_been_classified_as_a_Variant_of_Uncertain_Significance.|Functionally-validated_splicing_mutation:RNA_Studies
NM_007294.3:c.441G>C	BRCA1	missense_variant,splice_region_variant	102394	3	15322	2	4	1	rs748876625	Hereditary cancer-predisposing syndrome	220023	222678	_familial_1|not_specified	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C2676676,OMIM:604370|MedGen:CN169374	-	NC_000017.10:g.41256139C>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(4)	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):P38398#VAR_070464|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:2289073	-	BRCA1:672	SO:0001619|non-coding_transcript_variant	1	748876625	-	Invitae|Michigan_Medical_Genetics_Laboratories,University_of_Michigan|Ambry_Genetics|Color|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories	Uncertain_significance|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Uncertain_significance	2018-10-22|2016-04-21|2019-07-05|2018-08-01|2016-08-25|2019-04-04	2019-03-28|2016-04-21|2020-02-26|2018-11-06|2017-08-01|2019-08-05	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline	SCV000260248|SCV000267682|SCV000275598|SCV000911279|SCV000605876|SCV001160449	_familial_1|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified	This_sequence_change_replaces_leucine_with_phenylalanine_at_codon_147_of_the_BRCA1_protein_(p.Leu147Phe)._The_leucine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_leucine_and_phenylalanine._This_variantÂ¬â€ also_falls_at_the_last_nucleotide_of_exon_6_of_the_BRCA1_coding_sequence,Â¬â€ which_is_part_of_the_consensus_splice_site_for_this_exon._This_variant_is_present_in_population_databases_(rs748876625,_ExAC_frequency_<0.01%)._This_variant_has_been_reported_in_an_individual_with_a_personal_or_family_history_of_breast_and/or_ovarian_cancer_(PMID:_23231788)._This_variant_has_also_been_reported_in_individuals_with_breast_cancer_in_the_Leiden_Open-source_Variation_Database_(PMID:_21520333):_however,_in_two_of_those_individuals,_pathogenic_alleles_were_also_identified_in_BRCA1_or_BRCA2,_which_suggests_that_this_c.441G>C_variant_was_not_the_primary_cause_of_disease._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_220023)._One_experimental_study_has_shown_that_BRCA1_protein_carrying_this_missense_change_restored_growth_and_cisplatin_sensitivity_to_BRCA1-null_mouse_embryonic_stem_cells_(PMID:_23867111)._However,_another_experimental_study_using_a_phage_display_assay_has_shown_that_this_missense_change_resulted_in_decreased_E3_ligase_activity_compared_to_wild-type_protein_(PMID:_25823446)._Nucleotide_substitutions_within_the_consensus_splice_site_are_relatively_common_causes_of_aberrant_splicing_(PMID:_17576681,_9536098)._Algorithms_developed_to_predict_the_effect_of_nucleotide_changes_on_RNA_splicing_suggest_that_this_variant_may_alter_RNA_splicing,_but_this_prediction_has_not_been_confirmed_by_published_transcriptional_studies._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.||Last_nucleotide_of_exon:Intact_protein_function_observed_in_appropriate_functional_assay(s):Well-characterized_mutation_at_same_position:Other_data_supporting_pathogenic_classification|||The_BRCA1_c.441G>C:_p.Leu147Phe_variant_(rs748876625)_is_reported_in_the_literature_in_individuals_with_hereditary_breast_and_ovarian_cancer_syndrome_(Michils_2012,_Moghadasi_2013),_and_reported_multiple_times_in_the_LOVD_BRCA1_database_(see_link)._This_variant_is_also_reported_in_ClinVar_(Variation_ID:_220023)._One_functional_study_suggests_the_variant_is_neutral_based_on_its_ability_to_restore_growth_and_cisplatin_sensitivity_in_BRCA-null_mouse_embryonic_stem_cells_(Bouwman_2013)._However,_another_functional_study_suggests_the_variant_is_deleterious_as_the_variant_protein_displays_decreased_E3_ligase_activity_compared_to_wild_type_protein_(Starita_2015)._This_variant_is_found_in_the_general_population_with_an_overall_allele_frequency_of_0.002%_(5/281702_alleles)_in_the_Genome_Aggregation_Database._The_leucine_at_codon_147_is_highly_conserved_and_the_variant_is_located_in_the_last_nucleotide_of_the_exon._Computational_analyses_(SIFT,_PolyPhen-2,_Alamut_v.2.11)_predict_that_this_variant_is_deleterious_and_may_alter_splicing_by_weakening_the_nearby_canonical_donor_splice_site._However,_based_on_available_information,_the_significance_of_this_variant_is_uncertain_at_this_time._REFERENCES_Bouwman_P_et_al._A_high-throughput_functional_complementation_assay_for_classification_of_BRCA1_missense_variants._Cancer_Discov._2013_Oct:3(10):1142-55._Link_to_LOVD_BRCA1_database:_https://databases.lovd.nl/shared/variants/BRCA1#object_id
NM_032043.2:c.2119C>T	BRIP1	missense_variant	102436	6	15418	1	-	-	-	-	234570	232001	_complementation_group_J|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:CN517202	-	NC_000017.10:g.59821931G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(4)	-	single_nucleotide_variant	SO:0001483	-	-	BRIP1:83990	SO:0001583|missense_variant	1	764803896	-	GeneDx|Invitae|Ambry_Genetics|Color|Mendelics	Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2018-11-12|2018-12-07|2018-06-20|2018-08-31|2019-05-28	2019-01-29|2019-03-28|2020-02-26|2018-11-06|2019-10-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|unknown	SCV000279500|SCV000291003|SCV000661503|SCV000909769|SCV001140763	_complementation_group_J|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast	This_variant_is_denoted_BRIP1_c.2119C>T_at_the_cDNA_level,_p.Arg707Cys_(R707C)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Cysteine_(CGT>TGT)._This_variant_was_observed_in_an_individual_with_Fanconi_Anemia-J_who_also_had_a_second_BRIP1_missense_variant_and_weak_BRIP1_protein_expression_on_Western_blot_analysis_(Levitus_2005)._However,_as_phase_was_not_described,_we_cannot_be_certain_that_Arg707Cys_was_in_trans_with_the_second_missense_variant._In_vitro_functional_assays_suggests_this_variant_partially_impairs_helicase_activity_compared_to_wild_type_(Bhari_2018)._BRIP1_Arg707Cys_was_not_observed_at_a_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_helicase_domain_(Cantor_2011)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_it_is_unclear_whether_BRIP1_Arg707Cys_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|This_sequence_change_replaces_arginine_with_cysteine_at_codon_707_of_the_BRIP1_protein_(p.Arg707Cys)._The_arginine_residue_is_highly_conserved_and_there_is_a_large_physicochemical_difference_between_arginine_and_cysteine._This_variant_is_present_in_population_databases_(rs764803896,_ExAC_0.009%)._This_variant_has_been_reported_in_an_individual_affected_with_Fanconi_anemia_type_J_(PMID:_16116423)._A_second_BRIP1_missense_change,_c.1941G>C_(p.Trp647Cys),_was_also_identified_in_that_individual_but_whether_these_two_variants_were_the_cause_of_disease_in_that_individual_remains_uncertain._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_234570)._This_variant_has_been_reported_to_affect_BRIP1_protein_function_(PMID:_29788478)._The_BRIP1_gene_is_also_known_as_FANCJ_in_the_literature._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|Insufficient_or_conflicting_evidence:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||
NM_032043.2:c.139C>G	BRIP1	missense_variant	102696	51	15420	9	5&4	0&1	rs28903098	Breast cancer, early-onset&not provided	4736	19775	Neoplasm_of_ovary|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Fanconi_anemia,_complementation_group_J|Breast_cancer,_early-onset|not_specified|BRIP1-Related_Disorders|not_provided	-	Human_Phenotype_Ontology:HP:0100615,MedGen:C0919267,OMIM:167000,SNOMED_CT:123843001|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836860,OMIM:609054|MedGen:C4016951|MedGen:CN169374|MedGen:CN239206|MedGen:CN517202	-	NC_000017.10:g.59937223G>C	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(12)	-	single_nucleotide_variant	SO:0001483	Illumina:903207|OMIM_Allelic_Variant:605882.0001	-	BRIP1:83990	SO:0001583|missense_variant	1	28903098	-	OMIM|Genetic_Services_Laboratory,_University_of_Chicago|Ambry_Genetics|GeneKor_MSA|Color|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Counsyl|Mendelics|Counsyl|GeneDx|Invitae|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Illumina_Clinical_Services_Laboratory,Illumina|Mendelics	Pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_benign|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_benign|Uncertain_significance|Uncertain_significance|Uncertain_significance	2019-04-19|2018-01-17|2019-11-07|2018-08-01|2016-06-07|2018-10-31|2019-06-07|2016-08-18|2018-07-02|2016-08-18|2018-12-06|2019-02-27|2018-11-01|2019-04-05|2019-05-28	2019-04-19|2018-04-26|2020-02-26|2018-08-08|2018-11-06|2018-11-14|2019-09-24|2016-11-23|2018-08-20|2016-11-23|2019-01-29|2019-03-14|2020-03-06|2019-04-05|2019-10-22	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|germline|unknown|unknown|unknown|germline|germline|germline|germline|unknown	SCV000025178|SCV000593776|SCV000186330|SCV000821954|SCV000902624|SCV000895119|SCV000699663|SCV000489947|SCV000839405|SCV000489948|SCV000150033|SCV000255146|SCV000600892|SCV000914255|SCV001140808	Breast_cancer,_early-onset|Breast_cancer,_early-onset|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast/Fanconi_anemia,_complementation_group_J|not_specified|Fanconi_anemia,_complementation_group_J|Fanconi_anemia,_complementation_group_J|Neoplasm_of_ovary|not_provided|not_provided|not_provided|BRIP1-Related_Disorders|Familial_cancer_of_breast	||Conflicting_evidence||||Variant_summary:_BRIP1_c.139C>G_(p.Pro47Ala)_results_in_a_non-conservative_amino_acid_change_located_in_the_Helicase_superfamily_1/2,_ATP-binding_domain,_DinG/Rad3-type_and_Helicase-like,_DEXD_box_c2_type_domain_of_the_encoded_protein_sequence._Five_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._Multiple_functional_assays_have_been_performed_to_assess_the_effect_of_this_variant_on_BRIP1_properties._Based_on_these_results,_the_variant_may_reduce_ATPase_and_helicase_functions,_however,_mutant_protein_is_fully_soluble_and_can_still_interact_with_BRCA1._Therefore,_the_variant's_role_in_tumorigenesis_remains_unclear._The_variant_allele_was_found_at_a_frequency_of_0.00026_in_257860_control_chromosomes,_predominantly_at_a_frequency_of_0.00047_within_the_Non-Finnish_European_subpopulation_in_the_gnomAD_database,_including_1_homozygote._The_observed_variant_frequency_within_Non-Finnish_European_control_individuals_in_the_gnomAD_database_is_approximately_7_fold_of_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_BRIP1_causing_Hereditary_Breast_and_Ovarian_Cancer_phenotype_(6.3e-05),_strongly_suggesting_that_the_variant_is_a_benign_polymorphism._c.139C>G_has_been_reported_in_the_literature_in_individuals_affected_with_cancer_including_Hereditary_Breast_and_Ovarian_Cancer,_colorectal_cancer_and_pancreatic_cancer_but_also_in_controls._Co-occurrences_with_pathogenic_variants_have_been_reported_(BRCA1_c.5266dup,_p.Gln1756ProfsX74:_PALB2_c.1240C>T,_p.Arg414X:_BRCA2_c.8327T>G,_p.L2776X:_MSH2_c.942+3A>T),_providing_supporting_evidence_for_a_benign_role._The_variant_was_also_reported_in_the_FLOSSIES_database_in_5_women_older_than_age_70_years_who_have_never_had_cancer,_providing_further_supporting_evidence_for_a_benign_role._An_assocation_study,_Seal_2006,_did_not_find_an_associated_risk_for_Breast_Cancer_for_this_variant._12_ClinVar_submitters_(evaluation_after_2014)_cite_the_variant_as_uncertain_significance_(10x),_likely_benign_(1x)_and_once_as_pathogenic._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_VUS-possibly_benign.||||This_variant_is_denoted_BRIP1_c.139C>G_at_the_cDNA_level,_p.Pro47Ala_(P47A)_at_the_protein_level,_and_results_in_the_change_of_a_Proline_to_an_Alanine_(CCC>GCC)._In_vitro_functional_assays_have_shown_BRIP1_Pro47Ala_to_abolish_ATPase_activity_and_result_in_weak_helicase_activity_and_a_less_stable_protein_product_than_wild_type_(Cantor_2001,_Cantor_2004,_Gupta_2006,_Gupta_2007,_Wu_2008)._This_variant_has_been_observed_in_several_individuals_with_either_a_personal_or_family_history_of_breast_or_ovarian_cancer_and_at_least_one_individual_with_suspected_Lynch_syndrome:_however,_it_has_also_been_reported_in_control_subjects_and_individuals_with_pathogenic_variants_in_other_genes_explaining_their_phenotype_(Cantor_2001,_Seal_2006,_Kanchi_2014,_Yurgelun_2015,_Pinto_2016,_Pearlman_2017)._In_addition,_internal_data_are_not_highly_suggestive_of_pathogenicity,_including_the_frequency_of_observations_at_this_laboratory,_as_well_as_the_lack_of_a_reported_history_of_ovarian_cancer_in_many_internal_cases._BRIP1_Pro47Ala_was_observed_at_an_allele_frequency_of_0.02%_(69/277,164),_with_one_homozygous_observation,_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_Helicase_Domain_I_(Cantor_2001)._In_silico_analyses,_including_protein_predictors_and_evolutionary_conservation,_support_a_deleterious_effect._Due_to_the_conflicting_information,_we_consider_BRIP1_Pro47Ala_to_be_a_variant_of_uncertain_significance.|||The_BRIP1_c.139C>G_(p.Pro47Ala)_variant_has_been_reported_in_two_studies_in_which_it_is_found_in_a_heterozygous_state_in_a_total_of_five_patients,_all_with_a_family_history_of_breast_cancer_(Cantor_et_al._2001:_Seal_et_al._2006)._Only_the_BRIP1_gene_was_screened_in_both_studies._The_p.Pro47Ala_variant_was_also_detected_in_a_heterozygous_state_in_four_of_2081_controls_who_were_46_years_of_age_at_the_time_of_study_(Seal_et_al._2006)._Based_on_age_of_the_individuals,_disease_status_cannot_be_fully_determined_in_the_control_cohort._Additionally,_the_p.Pro47Ala_variant_is_reported_at_a_frequency_of_0.00038_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Functional_studies_in_cultured_cells_demonstrated_that_the_p.Pro47Ala_variant_protein_has_a_reduced_half-life_compared_to_wild_type_protein_and_also_exhibits_complete_loss_of_ATPase_and_helicase_activity_(Cantor_et_al._2001:_Cantor_et_al._2004)._The_evidence_for_this_variant_is_limited._The_p.Pro47Ala_variant_is_therefore_classified_as_a_variant_of_unknown_significance_but_suspicious_for_pathogenicity_for_BRIP1-related_disorders._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.|
NM_007194.3:c.1427C>T	CHEK2	missense_variant	100144	52	15420	3	4&4	1&1	rs142763740	Hereditary cancer-predisposing syndrome&not provided	128060	133517	_susceptibility_to|not_specified|CHEK2-Related_Cancer_Susceptibility|not_provided	-	Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1527249|MedGen:C1858433|MedGen:CN169374|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29090054G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(8)	-	single_nucleotide_variant	SO:0001483	Illumina:655839	-	CHEK2:11200	SO:0001583|missense_variant	17	142763740	-	Ambry_Genetics|Institute_for_Biomarker_Research,Medical_Diagnostic_Laboratories,_L.L.C.|GeneID_Lab_-_Advanced_Molecular_Diagnostics|Color|GeneKor_MSA|Invitae|HudsonAlpha_Institute_for_Biotechnology,_HudsonAlpha_Institute_for_Biotechnology|Counsyl|Mendelics|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Illumina_Clinical_Services_Laboratory,Illumina|Illumina_Clinical_Services_Laboratory,Illumina|Genetic_Services_Laboratory,_University_of_Chicago|Illumina_Clinical_Services_Laboratory,Illumina	Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic	2019-08-16|2017-02-14|2017-09-07|2018-10-03|2018-08-01|2018-12-30|2018-04-16|2017-10-06|2018-07-02|2015-11-20|2019-01-07|2018-12-10|2016-10-14|2016-09-30|2016-06-14|2016-06-14|2016-11-21|2017-04-27	2020-02-26|2017-02-16|2017-09-11|2018-11-06|2018-08-08|2019-03-28|2018-05-24|2018-06-20|2018-08-20|2016-03-03|2019-01-29|2020-03-06|2018-01-25|2018-01-29|2016-10-18|2016-10-18|2017-07-05|2019-02-01	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|germline|germline	SCV000186804|SCV000576430|SCV000680448|SCV000689655|SCV000821724|SCV000254925|SCV000778585|SCV000785095|SCV000839455|SCV000266166|SCV000149910|SCV000601155|SCV000698777|SCV000806869|SCV000437713|SCV000437714|SCV000594113|SCV000914986	_susceptibility_to|not_provided|not_provided|not_provided|not_provided|Colorectal_cancer|Neoplasm_of_the_breast|not_specified|CHEK2-Related_Cancer_Susceptibility	Detected_in_individual_satisfying_established_diagnostic_critera_for_classic_disease_without_a_clear_mutation:Deficient_protein_function_in_appropriate_functional_assay(s)|||||This_sequence_change_replaces_threonine_with_methionine_at_codon_476_of_the_CHEK2_protein_(p.Thr476Met)._The_threonine_residue_is_highly_conserved_and_there_is_a_moderate_physicochemical_difference_between_threonine_and_methionine._This_variant_is_present_in_population_databases_(rs142763740,_ExAC_0.07%)._This_variant_has_been_reported_in_individuals_affected_with_breast_cancer_(PMID:_21244692),_endometrial_cancer_(PMID:_27443514),_colorectal_cancer_(PMID:Â¬â€ 28944238),_prostate_cancer_(PMID:Â¬â€ 29368341,Â¬â€ 29520813),_and_in_a_male_with_breast_and_colon_cancer_(PMID:_28008555)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128060)._Experimental_studies_have_shown_that_this_missense_change_disrupts_CHEK2_kinase_activity_in_vitro_and_impairs_DNA_damage_response_in_a_yeast_assay_(PMID:_22114986,_22419737)._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||||This_variant_is_denoted_CHEK2_c.1427C>T_at_the_cDNA_level,_p.Thr476Met_(T476M)_at_the_protein_level,_and_results_in_the_change_of_a_Threonine_to_a_Methionine_(ACG>ATG)._This_variant_has_been_reported_in_individuals_with_a_personal_and/or_family_history_of_breast,_pancreatic,_or_prostate_cancer_(Desrichard_2011,_Le_Calvez-Kelm_2011,_Hu_2015,_Leedom_2016,_Pritzlaff_2016,_Shirts_2016,_Frey_2017,_Isaacsson_Velho_2018,_Schubert_2018,_Wu_2018)._This_variant_was_shown_in_an_in_vitro_study_to_abolish_kinase_activity,_and_was_shown_in_an_in_vivo_study_to_impair_CHEK2-mediated_response_to_DNA_damage_(Desrichard_2011,_Roeb_2012)._A_different_nucleotide_change_(CHEK2_c.1427C>A)_resulting_in_the_same_amino_acid_substitution_was_identified_in_a_patient_with_a_clinical_diagnosis_of_Li-Fraumeni_syndrome_(Sadri_2014)._Although_this_variant_was_observed_in_large_population_cohorts,_population_data_in_this_region_of_CHEK2_are_not_considered_reliable_due_to_high_pseudogene_homology_(Lek_2016)._CHEK2_Thr476Met_is_located_in_the_protein_kinase_domain_(Cai_2009,_Roeb_2012)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_the_currently_available_evidence,_we_consider_CHEK2_Thr476Met_to_be_a_likely_pathogenic_variant.|The_best_available_variant_frequency_is_uninformative._Statistically_enriched_in_patients_compared_to_ethnically_matched_controls._Found_in_at_least_one_symptomatic_patient._Predicted_to_have_a_damaging_effect_on_the_protein._Occurs_in_a_single_case_with_an_otherwise_positive_result._Assessment_of_experimental_evidence_suggests_this_variant_results_in_abnormal_protein_function.||||Across_three_studies,_the_c.1427C>T_(p.Thr476Met),_was_reported_in_five_of_1,955_breast_cancer_patients_(Le_Calvez-Kelm_et_al._2011:_Desrichard_et_al._2011:_Angelova_et_al._2012)._The_variant_was_absent_from_a_total_of_1,622_controls,_but_is_reported_at_a_frequency_of_0.00068_in_the_European_(Non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Desrichard_et_al._(2011)_developed_an_in_vitro_kinase_activity_assay_to_assess_the_activity_of_missense_variants_in_CHEK2._In_this_assay_the_p.Thr476Met_variant_demonstrated_no_kinase_activity_and_was_similar_to_a_known_non-functional_kinase_variant_of_CHEK2._In_addition,_Roeb_et_al._(2012)_developed_a_yeast-based_in-vivo_functional_assay_to_assess_the_effect_of_CHEK2_variants_on_the_repair_of_DNA_damage._Cells_with_wild-type_CHEK2_repaired_the_DNA_damage_while_cells_with_a_known_non-functional_variant_of_CHEK2_did_not._The_p.Thr476Met_variant_was_shown_to_have_loss_of_function_by_this_DNA_damage_response_assay._Based_on_the_evidence,_the_p.Thr476Met_variant_is_classified_as_likely_pathogenic_for_breast_cancer.||The_CHEK2_c.1427C>T_(p.Thr476Met)_missense_variant,_also_referred_to_as_c.1556C>T_(p.Thr519Met),_was_reported_in_five_of_1,955_breast_cancer_patients_(Le_Calvez-Kelm_et_al._2011:_Desrichard_et_al._2011:_Angelova_et_al._2012)._The_variant_was_absent_from_a_total_of_1,622_controls,_but_is_reported_at_a_frequency_of_0.00068_in_the_European_(non-Finnish)_population_of_the_Exome_Aggregation_Consortium._Desrichard_et_al._(2011)_developed_an_in_vitro_kinase_activity_assay_to_assess_the_activity_of_missense_variants_in_CHEK2._In_this_assay_the_p.Thr476Met_variant_demonstrated_no_kinase_activity_and_was_similar_to_a_known_non-functional_kinase_variant_of_CHEK2._In_addition,_Roeb_et_al._(2012)_developed_a_yeast-based_in-vivo_functional_assay_to_assess_the_effect_of_CHEK2_variants_on_the_repair_of_DNA_damage._Cells_with_wild_type_CHEK2_repaired_the_DNA_damage_while_cells_with_a_known_non-functional_variant_of_CHEK2_did_not._The_p.Thr476Met_variant_was_shown_to_have_loss_of_function_by_this_DNA_damage_response_assay._Based_on_the_evidence,_the_p.Thr476Met_variant_is_classified_as_pathogenic_for_CHEK2-related_cancer_susceptibility._This_variant_was_observed_by_ICSL_as_part_of_a_predisposition_screen_in_an_ostensibly_healthy_population.
NM_007194.3:c.1283C>T	CHEK2	missense_variant	102268	8	15434	1	5&5&5&5	2&1&1&1	rs137853011	Hereditary cancer-predisposing syndrome&Familial cancer of breast&Breast and colorectal cancer, susceptibility to&not provided	5603	20642	Osteosarcoma|Malignant_tumor_of_prostate|Neoplasm_of_the_breast|Hereditary_breast_and_ovarian_cancer_syndrome|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Colorectal_cancer|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|CHEK2-Related_Cancer_Susceptibility|not_provided	-	Human_Phenotype_Ontology:HP:0002669,MeSH:D012516,MedGen:C0029463,OMIM:259500,Orphanet:ORPHA668,SNOMED_CT:21708004|Human_Phenotype_Ontology:HP:0012125,MedGen:C0376358,OMIM:176807,SNOMED_CT:399068003|Human_Phenotype_Ontology:HP:0100013,MeSH:D001943,MedGen:C1458155,Orphanet:ORPHA180250,SNOMED_CT:126926005|MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1527249|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C3469522|MedGen:CN239278|MedGen:CN517202	-	NC_000022.10:g.29091207G>A	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(5),Pathogenic(11),Uncertain_significance(1)	-	single_nucleotide_variant	SO:0001483	Illumina:203534|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2833351|OMIM_Allelic_Variant:604373.0014|UniProtKB_(protein):O96017#VAR_022463	-	CHEK2:11200	SO:0001583|missense_variant	1	137853011	-	OMIM|Genetic_Services_Laboratory,_University_of_Chicago|Ambry_Genetics|Color|GeneKor_MSA|Invitae|Counsyl|Mendelics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Illumina_Clinical_Services_Laboratory,Illumina|Illumina_Clinical_Services_Laboratory,Illumina|Fulgent_Genetics,Fulgent_Genetics|Integrated_Genetics/Laboratory_Corporation_of_America|Illumina_Clinical_Services_Laboratory,Illumina	risk_factor|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic	2005-02-15|2017-02-21|2019-10-30|2015-02-16|2018-08-01|2019-01-08|2017-05-22|2018-07-02|2017-06-05|2015-11-20|2019-01-02|2019-03-22|2018-06-01|2016-06-14|2016-06-14|2017-05-18|2019-01-15|2017-09-05	2017-11-21|2017-07-05|2020-02-26|2016-07-05|2018-08-08|2019-03-28|2017-06-22|2018-08-20|2018-06-14|2016-03-03|2019-01-29|2020-03-06|2019-07-12|2016-10-18|2016-10-18|2017-05-23|2019-09-24|2019-02-01	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline	SCV000026135|SCV000594114|SCV000187227|SCV000292126|SCV000821728|SCV000253983|SCV000677740|SCV000839461|SCV000839938|SCV000266068|SCV000149903|SCV000601148|SCV000892318|SCV000437716|SCV000437715|SCV000611259|SCV000698769|SCV000914987	Breast_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|Colorectal_cancer|Neoplasm_of_the_breast|Familial_cancer_of_breast/Li-Fraumeni_syndrome_2/Osteosarcoma/Malignant_tumor_of_prostate|Hereditary_breast_and_ovarian_cancer_syndrome|CHEK2-Related_Cancer_Susceptibility	||In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species:Significant_disease_association_in_appropriately_sized_case-control_study(ies):Good_segregation_with_disease_(lod_1.5-3_
NM_007194.3:c.539G>A	CHEK2	missense_variant	102704	5	15420	1	5	0	rs137853009	Prostate cancer, somatic	5596	20635	_somatic|not_specified|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C4015779|MedGen:CN169374|MedGen:CN517202	-	NC_000022.10:g.29121018C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(7)	-	single_nucleotide_variant	SO:0001483	OMIM_Allelic_Variant:604373.0007|UniProtKB_(protein):O96017#VAR_019110	-	CHEK2:11200	SO:0001583|missense_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	3	137853009	-	OMIM|Ambry_Genetics|GeneKor_MSA|Color|Invitae|Counsyl|Mendelics|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America	Pathogenic|Uncertain_significance|Uncertain_significance|Likely_benign|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2003-02-01|2019-02-07|2018-08-01|2015-04-23|2018-12-27|2016-10-27|2019-05-28|2017-05-15|2018-08-27	2017-11-21|2020-02-26|2018-08-08|2018-11-06|2019-03-28|2016-11-23|2019-10-22|2019-01-29|2019-04-24	no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	somatic|germline|germline|germline|germline|unknown|unknown|germline|germline	SCV000026126|SCV000186257|SCV000822002|SCV000902809|SCV000260730|SCV000489564|SCV001141368|SCV000149934|SCV000917240	_somatic|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|not_provided|not_specified	|Conflicting_evidence|||This_sequence_change_replaces_arginine_with_histidine_at_codon_180_of_the_CHEK2_protein_(p.Arg180His)._The_arginine_residue_is_highly_conserved_and_there_is_a_small_physicochemical_difference_between_arginine_and_histidine._This_variant_is_present_in_population_databases_(rs137853009,_ExAC_0.01%)._This_variant_has_been_reported_in_individuals_with_prostate_cancer,_breast_cancer,_colorectal_cancer,_and_neuroblastoma_(PMID:_12533788,_12454775,_27978560,_23334666,Â¬â€ 30086788)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_5596)._Experimental_studies_have_shown_that_this_variant_results_in_slightly_reduced_expression,_stability,_and_kinase_activity_(PMID:_16982735,_22114986),_but_resembles_wild-type_CHEK2_protein_in_response_to_DNA_damage_(PMID:_16982735)._The_clinical_significance_of_these_results_is_not_known._In_summary,_the_available_evidence_is_currently_insufficient_to_determine_the_role_of_this_variant_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||This_variant_is_denoted_CHEK2_c.539G>A_at_the_cDNA_level,_p.Arg180His_(R180H)_at_the_protein_level,_and_results_in_the_change_of_an_Arginine_to_a_Histidine_(CGC>CAC)._This_variant_has_been_observed_in_breast,_colon,_prostate,_and_neuroblastoma_cancer_cases_including_an_individual_with_bilateral_breast_cancer_who_also_carried_the_common_CHEK2_pathogenic_variant,_1100delC_(Sodha_2002,_Dong_2003,_Pugh_2013,_Pearlman_2016)._Functional_studies_demonstrated_somewhat_reduced_protein_expression,_stability,_and_kinase_activity_when_compared_to_wild_type,_but_normal_phosphorylation_in_response_to_DNA_damage_was_also_demonstrated_(Sodha_2006,_Desrichard_2011)._CHEK2_Arg180His_was_observed_at_an_allele_frequency_of_0.00963%_(1/10386)_in_individuals_of_African_ancestry_in_large_population_cohorts_(NHLBI_Exome_Sequencing_Project,_The_1000_Genomes_Consortium_2015,_Lek_2016)._Since_Arginine_and_Histidine_share_similar_properties,_this_is_considered_a_conservative_amino_acid_substitution._CHEK2_Arg180His_occurs_at_a_position_that_is_conserved_across_species_and_is_within_the_FHA_domain_(Roeb_2012)._In_silico_analyses_predict_that_this_variant_is_probably_damaging_to_protein_structure_and_function._Based_on_currently_available_evidence,_it_is_unclear_whether_CHEK2_Arg180His_is_a_pathogenic_or_benign_variant._We_consider_it_to_be_a_variant_of_uncertain_significance.|Variant_summary:_CHEK2_c.539G>A_(p.Arg180His)_results_in_a_non-conservative_amino_acid_change_located_in_the_Forkhead-associated_(FHA)_domain_of_the_encoded_protein_sequence._Three_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_6.8e-05_in_279394_control_chromosomes_(gnomAD_and_publication)._This_frequency_is_not_significantly_higher_than_expected_for_a_pathogenic_variant_in_CHEK2_causing_Hereditary_Breast_and_Ovarian_Cancer_(6.8e-05_vs_0.00031),_allowing_no_conclusion_about_variant_significance._c.539G>A_has_been_reported_in_the_literature_in_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer_(Desrichard_2011,_Dong_2003,_Pearlman_2016,_Penkert_2018,_Sodha_2002,_van_Puijenbroek_2005,_Young_2016)._These_report(s)_do_not_provide_unequivocal_conclusions_about_association_of_the_variant_with_Hereditary_Breast_and_Ovarian_Cancer._Co-occurrences_with_other_pathogenic_variant(s)_have_been_reported_(ATM,_p.Glu1978X:_CHEK2_c.1100delC),_providing_supporting_evidence_for_a_benign_role._Functional_studies_indicate_that_the_variant_slightly_effects_protein_expression,_stability_and_kinase_activity_as_measured_by_activation_in_response_to_etoposide_induced_DNA_damage_(Sodha_2002)._However,_this_data_does_not_allow_convincing_conclusions_about_the_variant_effect._Four_ClinVar_submissions_from_other_clinical_diagnostic_laboratories_(evaluation_after_2014)_cites_the_variant_as_uncertain_significance._Based_on_the_evidence_outlined_above,_the_variant_was_classified_as_uncertain_significance.
NM_007194.3:c.483_485del	CHEK2	inframe_deletion	102706	3	15426	1	-	-	-	-	141783	151497	_susceptibility_to|not_provided	-	MeSH:D061325,MedGen:C0677776,Orphanet:ORPHA145|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1858433|MedGen:CN517202	-	NC_000022.10:g.29121072_29121074TCT[1]	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(6)	-	Microsatellite	SO:0000289	Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2841958	-	CHEK2:11200	SO:0001822|inframe_deletion,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	587782008	-	Ambry_Genetics|Color|Invitae|Counsyl|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Integrated_Genetics/Laboratory_Corporation_of_America|PreventionGenetics,PreventionGenetics|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Dr._Peter_K._Rogan_Lab,Western_University	Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Likely_pathogenic	2019-08-30|2018-06-01|2018-12-28|2016-08-23|2015-11-20|2018-08-17|2016-07-10|2017-06-15|2019-07-03|2015-12-22	2020-02-26|2018-11-06|2019-03-28|2016-11-23|2016-03-03|2019-01-29|2018-01-25|2018-01-29|2020-03-06|2015-12-22	criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided	germline|germline|germline|unknown|germline|germline|germline|germline|germline|unknown	SCV000185293|SCV000903081|SCV000255306|SCV000489121|SCV000266065|SCV000211012|SCV000698807|SCV000806882|SCV000889336|SCV000262585	_susceptibility_to|not_provided|not_provided|not_provided|not_provided|Hereditary_breast_and_ovarian_cancer_syndrome	Deficient_protein_function_in_appropriate_functional_assay(s):Structural_Evidence:In_silico_models_in_agreement_(deleterious)_and/or_completely_conserved_position_in_appropriate_species||This_sequence_change_deletes_3_nucleotides_from_exon_4_of_the_CHEK2_mRNA_(c.483_485delAGA)._This_leads_to_the_deletion_of_1_amino_acid_residue_in_the_CHEK2_protein_(p.Glu161del)_but_otherwise_preserves_the_integrity_of_the_reading_frame._This_variant_is_present_in_population_databases_(rs587782008,_ExAC_0.01%)._This_variant_has_been_reported_in_an_individual_affected_with_breast_cancer,_although_it_was_absent_from_the_tumors_of_affected_family_members_(PMID:_12442270)._It_was_also_observed_in_two_other_individuals_affected_with_breast_and/or_ovarian_cancer_(PMID:_26845104,_26898890)._This_variant_is_also_known_as_481_483del_in_the_literature._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_141783)._Experimental_studies_have_shown_that_this_missense_change_reduces_CHEK2_stability,_DNA_damage-induced_phosphorylation,_and_kinase_activity_in_vitro_(PMID:_16982735,_22114986)._In_summary,_this_variant_is_a_rare_in-frame_deletion_of_one_amino_acid_that_has_been_observed_in_affected_individuals_and_disrupts_CHEK2_activity_in_vitro._However,_it_is_unclear_whether_or_not_this_variant_segregates_with_disease_and_the_available_evidence_is_currently_insufficient_to_determine_its_role_in_disease._Therefore,_it_has_been_classified_as_a_Variant_of_Uncertain_Significance.|||This_in-frame_deletion_of_three_nucleotides_in_CHEK2_is_denoted_c.483_485delAGA_at_the_cDNA_level_and_p.Glu161del_(E161del)_at_the_protein_level._The_normal_sequence,_with_the_bases_that_are_deleted_in_brackets,_is_TAGA[delAGA]TCAC._This_variant_has_been_observed_in_several_individuals_with_a_personal_and_family_history_of_breast_cancer_and_was_absent_in_unaffected_controls_(Sodha_2002,_Desrichard_2011,_Caminsky_2016,_Shirts_2016)._Functional_studies_led_to_the_conclusion_that_CHEK2_Glu161del_was_likely_pathogenic_based_on_absent_kinase_activity,_reduced_protein_expression_and_stability,_and_reduced_activation_in_response_to_DNA_damage_(Sodha_2006,_Desrichard_2011)._CHEK2_Glu161del_was_not_observed_at_significant_allele_frequency_in_large_population_cohorts_(Lek_2016)._This_deletion_of_a_single_Glutamic_Acid_amino_acid_is_located_in_the_FHA_domain_(Cai_2009,_Roeb_2012)._In-silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_CHEK2_Glu161del_to_be_likely_pathogenic.|Variant_summary:_The_c.483_485delAGA_(p.Glu161del)_in_CHEK2_gene_is_an_in-frame_deletion_leading_to_removal_of_a_single_Glutamic_Acid_residue_in_a_region_that_is_conserved_across_species_and_is_located_in_the_FHA_domain._Functional_studies_have_shown_that_this_in-frame_deletion_reduces_CHEK2_stability,_DNA_damage-induced_phosphorylation_and_significantly_diminish_kinase_activity_in_vitro._The_variant_is_present_in_control_dataset_of_ExAC_at_a_low_frequency_of_0.000016_(2/122994_chrs_tested)_which_does_not_exceed_the_estimated_maximum_allele_frequency_for_a_pathogenic_allele_in_this_gene_(0.000028)._The_variant_was_identified_in_at_least_3_affected_individuals_(BRCA1/2_and_TP53_mutation_free._For_2_of_these_individuals_with_personal_and_family_history_of_BrC_segregation_analysis_was_not_performed_and_in_1_LFS_family_2_affected_individuals_did_not_carry_the_variant,_raising_the_question_about_pathogenicity_of_the_variant_of_interest._The_variant_of_interest_has_been_reported_as_Likely_Pathogenic/VUS_by_reputable_databases/clinical_laboratories._Additional_clinical,_segregation_and_population_data_needed_to_classify_this_variant_with_confidence._Taking_together,_based_on_the_results_of_the_functional_studies,_the_variant_was_classified_as_VUS-Possibly_Pathogenic.|||Sequenced_patient_with_familial_breast_cancer
NM_007194.3:c.470T>C	CHEK2	missense_variant	102706	369	15432	239	5&5&4&4	0&2&1&1	rs17879961	Li-Fraumeni syndrome 2&Hereditary cancer-predisposing syndrome&Breast and colorectal cancer, susceptibility to&not provided	5591	20630	Cancer_of_multiple_types,_susceptibility_to|Prostate_cancer,_susceptibility_to|Gastrointestinal_carcinoma|Adrenocortical_carcinoma|Familial_cancer_of_breast|Hereditary_cancer-predisposing_syndrome|Li-Fraumeni_syndrome_2|Breast_and_colorectal_cancer,_susceptibility_to|Colorectal_cancer,_susceptibility_to|Breast_cancer,_susceptibility_to|COLON_CANCER,_SUSCEPTIBILITY_TO|not_specified|not_provided	-	.|.|Human_Phenotype_Ontology:HP:0002672,MedGen:C0151544|Human_Phenotype_Ontology:HP:0006744,MeSH:D018268,MedGen:C0206686,Orphanet:ORPHA1501|MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1836482,OMIM:609265|MedGen:C1858433|MedGen:C1858438|MedGen:C3469522|MedGen:C4016820|MedGen:CN169374|MedGen:CN517202	-	NC_000022.10:g.29121087A>G	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Likely_pathogenic(7),Pathogenic(7),Uncertain_significance(3)	-	single_nucleotide_variant	SO:0001483	ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories:181664|OMIM_Allelic_Variant:604373.0002|UniProtKB_(protein):O96017#VAR_008555	-	CHEK2:11200	SO:0001583|missense_variant,SO:0001623|5_prime_UTR_variant,SO:0001627|intron_variant	1	17879961	-	OMIM|OMIM|OMIM|OMIM|Ambry_Genetics|Color|True_Health_Diagnostics|GeneKor_MSA|ITMI|Integrated_Genetics/Laboratory_Corporation_of_America|ARUP_Laboratories,_Molecular_Genetics_and_Genomics,_ARUP_Laboratories|Pathway_Genomics|Invitae|Counsyl|Mendelics|Human_Genome_Sequencing_Center_Clinical_Lab,Baylor_College_of_Medicine|Center_of_Medical_Genetics_and_Primary_Health_Care|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|Division_of_Genomic_Diagnostics,The_Children's_Hospital_of_Philadelphia|GeneDx|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|Mayo_Clinic_Genetic_Testing_Laboratories,Mayo_Clinic|PreventionGenetics,PreventionGenetics|Genetic_Services_Laboratory,_University_of_Chicago|Centre_for_Mendelian_Genomics,University_Medical_Centre_Ljubljana|GenomeConnect,_ClinGen	Pathogenic|risk_factor|risk_factor|risk_factor|Pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|not_provided|Uncertain_significance|Pathogenic|Likely_pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Pathogenic|Pathogenic|Likely_pathogenic|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Pathogenic|Pathogenic|Likely_pathogenic|Pathogenic|Uncertain_significance|not_provided	2006-11-01|2006-11-01|2006-11-01|2006-11-01|2018-06-20|2014-12-26|2017-11-16|2018-08-01|2013-09-19|2019-04-15|2019-01-02|2014-07-24|2019-01-09|2016-03-15|2018-07-02|2017-06-02|0000-00-00|2015-11-20|2018-05-03|2019-09-30|2019-04-01|2017-02-17|0000-00-00|2016-09-14|2017-06-13|2017-01-01|0000-00-00	2011-11-22|2011-11-22|2011-11-22|2011-11-22|2020-02-26|2016-07-05|2018-03-08|2018-08-08|2014-05-29|2019-09-24|2019-08-05|2014-08-08|2019-03-28|2017-06-22|2018-08-20|2018-06-14|2019-08-31|2016-03-03|2018-05-04|2020-01-06|2019-07-12|2017-08-01|2017-10-31|2018-01-29|2017-07-05|2017-12-08|2019-01-30	no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided	germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|germline|unknown|unknown|germline|germline|germline|germline|germline|germline|germline|unknown|germline|germline|unknown|unknown	SCV000026118|SCV000026119|SCV000026120|SCV000026121|SCV000183804|SCV000292120|SCV000788004|SCV000821722|SCV000084709|SCV000698803|SCV001159433|SCV000189923|SCV000253984|SCV000677722|SCV000839491|SCV000839939|SCV000987254|SCV000266064|SCV000296968|SCV000149927|SCV000575329|SCV000601169|SCV000691835|SCV000806880|SCV000594119|SCV000747421|SCV000986797	Li-Fraumeni_syndrome_2|Colorectal_cancer,_susceptibility_to|Cancer_of_multiple_types,_susceptibility_to|Prostate_cancer,_susceptibility_to|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|Hereditary_cancer-predisposing_syndrome|not_specified|not_specified|not_specified|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Familial_cancer_of_breast|Breast_and_colorectal_cancer,_susceptibility_to|Breast_and_colorectal_cancer,_susceptibility_to|not_provided|not_provided|not_provided|not_provided|not_provided|Breast_cancer,_susceptibility_to|Gastrointestinal_carcinoma/Adrenocortical_carcinoma|Breast_cancer,_susceptibility_to/COLON_CANCER,_SUSCEPTIBILITY_TO	||||Significant_disease_association_in_appropriately_sized_case-control_study(ies):Deficient_protein_function_in_appropriate_functional_assay(s):Other_strong_data_supporting_pathogenic_classification|||||Variant_summary:_CHEK2_c.470T>C_(p.Ile157Thr)_results_in_a_non-conservative_amino_acid_change_located_in_the_Forkhead-associated_(FHA)_domain_(IPR000253)_of_the_encoded_protein_sequence._Four_of_five_in-silico_tools_predict_a_damaging_effect_of_the_variant_on_protein_function._The_variant_allele_was_found_at_a_frequency_of_0.0042_in_253524_control_chromosomes_in_the_gnomAD_database,_including_11_homozygotes._The_observed_variant_frequency_is_approximately_13.5_fold_of_the_estimated_maximal_expected_allele_frequency_for_a_pathogenic_variant_in_CHEK2_causing_Hereditary_Breast_and_Ovarian_Cancer_phenotype_(0.00031)._In_addition,_this_variant_has_been_reported_in_47/7325_European_American_women_(including_1_homozygote)_who_are_older_than_age_70_and_cancer_free_(in_the_FLOSSIES_database)._These_data_suggest_that_the_variant_is_benign_polymorphism._However,_c.470T>C_has_been_reported_in_the_literature_in_several_individuals_affected_with_Hereditary_Breast_and_Ovarian_Cancer._In_families_with_this_variant,_transmissions_of_the_variant_allele_and_transmissions_of_the_reference_allele_to_affected_individuals_was_reported_in_addition_to_unaffected_individuals_who_harbored_the_variant_(Allinen_2001,_Dong_2003,_Roeb_2012,_Bak_2014,_Cragun_2014,_Stradella_2018)._These_data_indicate_that_the_variant_is_likely_to_be_associated_with_disease_but_also_suggests_incomplete_segregation_and_incomplete_penetrance_associated_with_this_variant._Co-occurrences_with_other_pathogenic_variants_have_been_reported_in_CHEK2_as_well_as_in_other_genes_associated_with_cancer_(e.g._BRCA2_c.6468_6469delTC_[p.Gln2157fsX18]:_NBN_c.657_661delACAAA_[p.Lys219fsX16]:_BRCA1_c.3700_3704delGTAAA_[p.Val1234fsX8]:_CHEK2_c.444+1G>A:_CHEK2_1100delC_[p.Thr367fsX15]:_CHEK2_c.433C>T_[p.Arg145Trp]),_providing_supporting_evidence_for_a_benign_role,_though_in_some_of_these_cases_the_observed_phenotype_(earlier_onset),_could_also_suggest_an_additive_effect_(Stradella_2018)._Multiple_association_studies_have_produced_conflicting_results,_but_with_an_overall_consensus_for_the_variant_being_associated_with_a_moderate_increased_risk_for_breast_cancer_based_on_a_large_meta-analysis_by_Liu_2012_that_included_a_total_of_fifteen_case-control_studies_(19,621_cases_and_27,001_controls),_showing_a_significant_association_for_unselected_breast_cancer_(OR_
NM_007194.3:c.190G>A	CHEK2	missense_variant	102728	32	15404	5	4	1	rs141568342	not provided	128068	133525	_susceptibility_to|not_specified|not_provided	-	MedGen:C0006142,OMIM:114480,Orphanet:ORPHA227535,SNOMED_CT:254843006|MedGen:C0027672,SNOMED_CT:699346009|MedGen:C1858433|MedGen:CN169374|MedGen:CN517202	-	NC_000022.10:g.29130520C>T	_conflicting_interpretations	Conflicting_interpretations_of_pathogenicity	Uncertain_significance(9)	-	single_nucleotide_variant	SO:0001483	UniProtKB_(protein):O96017#VAR_019107|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano:2833882	-	CHEK2:11200	SO:0001623|5_prime_UTR_variant	1	141568342	-	Ambry_Genetics|True_Health_Diagnostics|GeneKor_MSA|Color|Invitae|Counsyl|Mendelics|GenomeConnect,_ClinGen|University_of_Washington_Department_of_Laboratory_Medicine,_University_of_Washington|GeneDx|Quest_Diagnostics_Nichols_Institute_San_Juan_Capistrano|PreventionGenetics,PreventionGenetics|CeGaT_Praxis_fuer_Humangenetik_Tuebingen|Integrated_Genetics/Laboratory_Corporation_of_America	Uncertain_significance|Likely_pathogenic|Uncertain_significance|Likely_pathogenic|Likely_pathogenic|Uncertain_significance|Uncertain_significance|not_provided|Uncertain_significance|Likely_pathogenic|Uncertain_significance|Uncertain_significance|Uncertain_significance|Uncertain_significance	2019-03-15|2018-03-16|2018-08-01|2018-06-18|2018-12-31|2016-06-14|2018-07-02|0000-00-00|2015-11-20|2018-09-10|2019-05-03|2017-11-29|2018-06-01|2017-10-20	2020-02-26|2018-06-26|2018-08-08|2018-11-06|2019-03-28|2016-11-23|2018-08-20|2019-01-30|2016-03-03|2019-01-29|2020-03-06|2018-01-29|2019-07-12|2019-04-24	criteria_provided,_single_submitter|no_assertion_criteria_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|no_assertion_provided|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter|criteria_provided,_single_submitter	germline|germline|germline|germline|germline|unknown|unknown|unknown|germline|germline|germline|germline|germline|germline	SCV000185901|SCV000805259|SCV000821997|SCV000902646|SCV000254934|SCV000488777|SCV000839503|SCV000986765|SCV000266168|SCV000149918|SCV000601160|SCV000806876|SCV000892320|SCV000917231	_susceptibility_to|not_provided|not_provided|not_provided|not_provided|not_specified	Insufficient_evidence:Conflicting_evidence||||This_sequence_change_replaces_glutamic_acid_with_lysine_at_codon_64_of_the_CHEK2_protein_(p.Glu64Lys)._The_glutamic_acid_residue_is_moderately_conserved_and_there_is_a_small_physicochemical_difference_between_glutamic_acid_and_lysine._This_variant_is_present_in_population_databases_(rs141568342,_ExAC_0.03%)._This_variant_has_been_observed_in_many_individuals_with_a_personal_and/or_family_history_of_breast,_prostate,_ovarian,_colorectal,_thyroid,_and_pancreatic_cancer_(PMID:_27616075,_22114986,_27779110,_24082139,_12533788,_26681312,_28135145,_26845104)._It_has_also_been_observed_to_segregate_with_CHEK2-related_cancers_in_several_families,_although_with_incomplete_penetrance_(Invitae,_External_communication)._ClinVar_contains_an_entry_for_this_variant_(Variation_ID:_128068)._Experimental_studies_have_shown_that_this_missense_change_leads_to_reduced_phosphorylation_and_partial_disruption_of_CHEK2_kinase_activity_(PMID:_16835864),_as_well_as_loss_of_DNA_damage_response_(PMID:_22419737)._In_summary,_the_currently_available_evidence_indicates_that_the_variant_is_pathogenic,_but_additional_data_are_needed_to_prove_that_conclusively._Therefore,_this_variant_has_been_classified_as_Likely_Pathogenic.|||Variant_interpretted_as_Likely_pathogenic_and_reported_on_01/08/2018_by_GTR_ID_Color._GenomeConnect_assertions_are_reported_exactly_as_they_appear_on_the_patient-provided_report_from_the_testing_laboratory._GenomeConnect_staff_make_no_attempt_to_reinterpret_the_clinical_significance_of_the_variant.|This_variant_was_shown_to_partially_reduce_CHEK2_protein_kinase_activity_(Wu_2006)._In_a_different_functional_assay_system_(Roeb_2012)_the_CHEK2_p.E64K_variant_was_also_shown_to_impact_CHEK2_protein_function|This_variant_is_denoted_CHEK2_c.190G>A_at_the_cDNA_level,_p.Glu64Lys_(E64K)_at_the_protein_level,_and_results_in_the_change_of_a_Glutamic_Acid_to_a_Lysine_(GAG>AAG)._This_variant_has_been_reported_in_individuals_with_personal_and/or_family_history_of_breast,_prostate,_or_pancreatic_cancer_(Dong_2003,_Wu_2006,_Desrichard_2011,_Roeb_2012,_Kraus_2016,_Shirts_2016,_Tung_2016,_Mandelker_2017)._Functional_analyses_have_shown_reduced_phosphorylation_and_kinase_activity_as_well_as_loss_of_DNA_damage_response_(Wu_2006,_Roeb_2012)._CHEK2_Glu64Lys_was_observed_at_an_allele_frequency_of_0.03%_(38/126,668)_in_individuals_of_European_ancestry_in_large_population_cohorts_(Lek_2016)._This_variant_is_located_in_the_SQ/TQ_domain_(Bartek_2001,_Desrichard_2011)._In_silico_analysis,_which_includes_protein_predictors_and_evolutionary_conservation,_supports_a_deleterious_effect._Based_on_currently_available_evidence,_we_consider_CHEK2_Glu64Lys_to_be_a_likely_pathogenic_variant.||||Variant_summary:_The_CHEK2_c.190G>A_(p.Glu64Lys)_variant_causes_a_missense_change_involving_the_alteration_of_a_conserved_nucleotide._2/3_in_silico_tools_predict_a_benign_outcome_for_this_variant_(SNPsandGO_not_captured_due_to_low_reliability_index)._One_DNA_damage_response_study_using_a_yeast-based_assay_showed_a_lack_of_response_due_to_the_variant_(Roeb_2012)._This_variant_was_found_in_44/277158_control_chromosomes_(gnomAD),_predominantly_observed_in_the_European_(Non-Finnish)_subpopulation_at_a_frequency_of_0.0003_(38/126668)._This_frequency_is_approximately_equal_to_the_estimated_maximal_expected_allele_frequency_of_a_pathogenic_CHEK2_variant_in_HBOC_phenotypes_(0.0003125),_suggesting_this_may_be_a_benign_polymorphism_found_primarily_in_the_populations_of_European_(Non-Finnish)_origin._However,_a_high-homology_CHEK2_pseudogene_may_confound_these_results_and_interpretation_must_be_performed_cautiously._This_variant_was_reported_in_multiple_patients_with_HBOC,_prostate_cancer,_and_CRC_(Wu_2006,_Pritchard_2016,_Kraus_2016,_Shirts_2016),_without_strong_evidence_for_pathogenicity,_including_one_report_where_it_co-occurred_with_likely_pathogenic_BMPR1A_c.969delT,_p.Cys323Trpfs*41_and_CHEK2_c.470T>C,_p.Ille157Thr_in_one_individual_with_CRC_(Rohlin_2016)._In_addition,_multiple_clinical_diagnostic_laboratories/reputable_databases_classified_this_variant_as_uncertain_significance._Taken_together,_this_variant_is_classified_as_a_VUS_until_more_definitive_functional_and_clinical_data_become_available.
